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R-(-)-Phenylephrine (PE) is the most commonly used nonprescription oral nasal decongestant 
in the United States. It is a selective α1-adrenergic receptor agonist and has many years of safe 
usage. However, the efficacy of PE is controversial, due to its extensive pre-systemic 
metabolism, which leads to low and variable oral bioavailability (38 ± 9%, mean ± SD). 
Sulfation plays a very important role in pre-systemic metabolism of PE. The sulfation of PE 
occurs at its phenolic group, which is the preferred structural feature of many sulfotransferase 
(SULT) substrates. Compounds with phenolic groups have similar structures to PE, which may 
share the same SULT isoforms with PE and have the potential to inhibit PE sulfation. Co-
administration of the phenolic compounds from the Food and Drug Administration’s (FDA) 
  
X 
 
“Generally Recognized as Safe” (GRAS) list, Everything Added to Food in the United States 
(EAFUS), or dietary supplements along with PE could be an effective strategy to inhibit the pre-
systemic sulfation of PE. The primary side effect of PE is hypertension. Since monoamine 
oxidase (MAO) inhibitors may increase the risk of hypertension, they should not be taken with 
PE. 
In order to increase the oral bioavailability and eventually improve the efficacy of PE, this 
research project aimed to investigate the feasibility of inhibiting the pre-systemic sulfation of PE 
with phenolic dietary compounds. Considering the safety issue, this research project also aimed 
to investigate whether these phenolic dietary compounds have inhibitory effects on MAO-A/B. 
A human colon adenocarcinoma epithelial cell line (LS180), which shows sulfation activity, 
was used as a model to test the effect of these phenolic compounds on the sulfation of PE. The 
extent of disappearance of PE was significantly (p < 0.05) decreased to the following (mean ± 
SEM, as % of control) when incubated with phenolic dietary compounds in LS180 cells for 14 - 
19 hrs: curcumin 24.5 ± 14.0%, guaiacol 51.3 ± 8.0%, isoeugenol 73.9 ± 4.3%, pterostilbene 
70.6 ± 4.2%, resveratrol 14.2 ± 28.0%, zingerone 52.4 ± 14.6%, and the combinations eugenol + 
propylparaben 42.6 ± 8.4%, vanillin + propylparaben 37.0 ± 11.2%, eugenol + propylparaben + 
vanillin + ascorbic acid 31.1 ± 10.9%, eugenol + vanillin 57.5 ± 20.6%, and pterostilbene + 
zingerone 36.5 ± 7.0%. The combinations of curcumin + resveratrol and curcumin + 
pterostilbene + resveratrol + zingerone almost completely inhibited PE disappearance.  
PE sulfate formation was inhibited 67.0 ± 4.2% (mean ± SEM, as % of control) by guaiacol 
and 71.7 ± 2.6% by pterostilbene + zingerone. The combinations of curcumin + resveratrol and 
curcumin + pterostilbene + resveratrol + zingerone inhibited ≥ 99% of PE sulfate formation. 
These results were consistent with those from analysis of the disappearance of PE in LS180 cells.  
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These phenolic inhibitors for sulfation were also tested to see whether they have any 
inhibitory effects on MAO-A or B. Significant inhibition was found with curcumin, guaiacol, 
isoeugenol, pterostilbene, resveratrol, and zingerone on both MAO-A and B. Further kinetic 
studies were conducted to investigate the concentration of an inhibitor at which the enzyme 
activity is reduced by half (IC50) (mean ± SEM) of these inhibitors. The most potent inhibitor for 
MAO-A was resveratrol (0.313 ± 0.008 μM) followed by isoeugenol (3.72 ± 0.20 μM), curcumin 
(12.9 ± 1.3 μM), pterostilbene (13.4 ± 1.5 μM), zingerone (16.3 ± 1.1 μM), and guaiacol (131 ± 6 
μM). The most potent inhibitor for MAO-B was pterostilbene (0.138 ± 0.013 μM), followed by 
curcumin (6.30 ± 0.11 μM), resveratrol (15.8 ± 1.3 μM), isoeugenol (102 ± 5 μM), and guaiacol 
(322 ± 27 μM). Since these phenolic compounds all have relatively low oral bioavailability, any 
MAO inhibition which could occur systemically is expected to be limited. Most inhibitory 
effects on MAO-A and B if any would be limited to the GI tract and liver. 
In conclusion, several compounds and combinations showed inhibition on PE sulfation in 
LS180 cell model, which may have potential to inhibit the pre-systemic sulfation of PE to 
improve its oral bioavailability. These compounds also showed the unexpected inhibition on 
human MAO-A and B with different potency, which could guide the selection of phenolic 
dietary compounds for further studies, along with the sulfation inhibition results and their 
pharmacokinetic (PK) properties such as bioavailability.   
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CHAPTER 1 
 
CLINICAL SIGNIFICANCE AND PHARMACOKINETIC PROBLEM OF 
PHENYLEPHRINE 
 
 
 
 
1.1 CLINICAL SIGNIFICANCE AS ORAL NASAL DECONGESTANT 
Sympathomimetic amines: PE, phenylpropanolamine, pseudoephedrine, and ephedrine are 
commonly used oral nasal decongestants and have a long history [1, 2]. Oral PE, 
phenylpropanolamine, and pseudoephedrine were approved as over-the-counter nasal 
decongestants by FDA in 1976 [3]. Ephedrine activates both α- and β- adrenergic receptors. 
Many adverse effects with ephedrine may be related to its non-selective adrenergic properties [4].  
Phenylpropanolamine and pseudoephedrine predominantly occupied the market until 2000. 
Phenylpropanolamine was withdrawn from the market because of its possible side effect 
(hemorrhagic stroke) and also its abuse [5, 6]. Due to the illegal manufacture of 
methamphetamine from pseudoephedrine, the retail stores in the United States have to put 
pseudoephedrine products “behind the counter”, require photo identification for sales, and keep 
personal information in a log for at least 2 years, as required by the Combat Methamphetamine 
Epidemic Act of 2005 [7]. PE is now the predominant nonprescription orally administered nasal 
decongestant. Oral PE has been used for many years as a systemic nasal decongestant at 10 mg 
dose to treat nasal or sinus congestion for the common cold, flu, allergic rhinitis, and sinusitis 
[3].  
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1.2 PHYSICOCHEMICAL PROPERTIES AND PHARMACOLOGY 
The physicochemical properties of PE are listed as follows: small, polar, molecular weight of 
167.21. The logP value is 0.117 ± 0.269 at 25 
o
C [8]. The logD value is -2.13 at pH 7.0 and 25 
o
C [8]. The estimated pKa values of hydroxyphenyl and amine groups are 9.8 and 9.2, 
respectively [8]. PE is ionized at physiological pH and thereby highly hydrophilic. The structure 
of PE is shown in Figure 1.1. Since PE has a single chiral carbon atom, there is a pair of 
enantiomers: R-(-)-PE and S-(+)-PE. The R-(-)-form activates α1-adrenergic receptors and is 
commercially used [2, 9]. Unlike catecholamines, PE does not contain a hydroxyl group at the 4-
position on the benzene ring. Because of the lack of the 4-hydroxyl group, PE is not a substrate 
of catechol-O-methyltransferase in the gastrointestinal tract, liver, and blood circulation, which 
explains less extensive pre-systemic metabolism, longer half-life and duration of action with PE 
compared to catecholamines such as dopamine, epinephrine, and norepinephrine [10].  
 
 
 
Figure 1.1. Structures of Phenylephrine Enantiomers  
 
The structures show the chiral center of PE is a carbon atom, generating a pair of enantiomers: R-
(-)-PE and S-(+)-PE.  
 
PE has promising pharmacological activity as a nasal decongestant. The mechanism is that 
PE stimulates the α1-adrenergic receptors expressed in peripheral vascular smooth muscle, 
causing vasoconstriction in the arterioles of nasal and sinus mucosa. Therefore, the nasal blood 
flow declines and nasal congestion is reduced [11]. PE is a relatively selective α1-
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adrenergic receptor agonist, but also a weak α2-adrenergic receptor agonist. It has negligible β-
adrenergic effects [7]. Instead of the indirect action on regulating endogenous catecholamines, 
the action produced by PE is through direct activation of α-adrenergic receptors. Due to its direct 
α-adrenergic agonist effect, PE is much more potent on vasoconstriction than indirect 
decongestants [7].  
1.3 EFFICACY AND SAFETY 
The efficacy of oral PE is controversial, due to its extensive pre-systemic metabolism which 
leads to low and variable oral bioavailability [12, 13]. A clinical efficacy study based on the 
effects of oral PE on nasal airway resistance shows that 10 mg PE is not significantly different 
from a placebo. A 25 mg dose PE reduces the maximal nasal airway resistance significantly 
compared to a placebo [3]. These findings also demonstrate that the lack of efficacy may be 
associated with inadequate plasma concentrations. In this study, the patient-reported effects of 
PE on congestion relief do not show consistent improvement compared with placebo [3].  
There is no severe safety issue with PE after being used for so many years. At a high dose 
level (50 mg), PE may cause increases in arterial blood pressure and declines in heart rate [14]. 
But at the approved therapeutic dose as oral nasal decongestant (10 mg), PE has limited effects 
on the cardiovascular system. Due to its hydrophilicity, which leads to low diffusional 
permeability, PE has less chance to cause central nervous system stimulation [7]. The primary 
side effect of PE is hypertension. Using MAO inhibitors together with PE should be avoided 
because they may increase the risk of hypertension by enhancing the hypertensive effect of α1-
adrenergic agonists. MAO inhibitors can inhibit pre-systemic and systemic metabolism of PE, 
resulting in the elevated level of PE in the systemic circulation [15]. Furthermore, the 
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metabolism of endogenous sympathomimetic amines in circulation and tissue could be inhibited 
by systemic exposure to MAO inhibitors [16]. 
1.4 ANALYTICAL METHODS  
In the early days, fluorimetry, gas chromatography, and liquid scintillation were used to 
determine PE levels in either biologic samples or pharmaceutical formulations [17-20]. Owing to 
the non-specificity of radioactivity measurement, and the inconvenience of gas chromatography 
usage, the application of high-performance liquid chromatography (HPLC) coupled with 
ultraviolet (UV), fluorescence (FLU), electrochemical (EC) detector, or mass spectrometry (MS) 
became more popular to quantitatively analyze PE. Table 1.1 summarizes the HPLC methods in 
the literature. These studies cover a variety of matrices, including extraction from different 
dosage forms such as nasal drops/spray, oral syrup/capsules/sachets, or injection, as well as 
biologic fluids like serum, plasma, or aqueous humor. Based on the complexity of serum and 
plasma, solid-phase extraction (SPE) is applied to clean up the samples. Since PE is a very polar 
compound with a phenyl ring, phenyl cartridges are appropriate for this purpose [21, 22]. 
Another choice is weak cation-exchange (WCX) cartridge, which is used since PE is positively 
charged below pH 9 [23]. Also due to this property, ion-pairing strategy for separation is 
performed successfully several times.  One of these studies even shows that adding ion-pairing 
reagents to the samples instead of mobile phase can increase the retention time of PE as well [24]. 
Some special columns, for example, cyano (CN), polyethylene glycol (PEG), pentafluorophenyl 
(PFP), and hydrophilic interaction liquid chromatography (HILIC) columns, are selected in order 
to have better retention for PE [25-30]. The low limit of detection (LLOD) and the low limit of 
quantification (LLOQ) vary among different methods, with the lowest limit of quantification as 
0.051 ng/mL in human serum [29].  
  
5 
 
None of the assays in the literature directly analyze PE metabolites. One of the studies 
detected PE sulfate and glucuronide by hydrolyzing them with enzymes to the parent compounds 
and then measuring the parent compounds [14]. Another study separated the radio-labeled PE 
and metabolites by column chromatography, solvent extraction, and thin-layer chromatography 
(TLC) and analyzed the fractions by liquid scintillation [19].     
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Table 1.1. HPLC Methods for Phenylephrine in Pharmaceutical Formulations and Biologic Fluids  
 
SPE: solid-phase extraction; WCX: weak cation-exchange; HILIC: hydrophilic interaction liquid chromatography; ODS: 
octadecylsilane; CN: cyano; PEG: polyethylene glycol; PFP: pentafluorophenyl; UV: ultraviolet; FLU: fluorescence; EC: 
electrochemical; MS: mass spectrometry; LLOD: the low limit of detection; LLOQ: the low limit of quantification.  
Matrix  
Sample 
Preparation   
Analytical 
Separation  
Method  
Column  Detection  
LLOD   
(ng/mL) 
LLOQ  
(ng/mL) 
Reference  
Dilute nose drops  
 
Ion pairing  C18  UV  
  
Ghanekar et al. 1978 [31] 
Dilute nasal spray  
 
Ion pairing  ODS UV  
  
Wilson et al. 1985 [32] 
Extraction from capsules  
 
Ion pairing  C8 UV  
  
Schieffer et al. 1984 [33] 
Human plasma  SPE (phenyl) 
 
C18  FLU 0.5 
 
Chien et al. 1985 [21] 
Aqueous solution  
  
C18  UV  
  
Gupta et al. 1986 [34] 
Human plasma  
   
EC  
  
Martinsson et al. 1986 [35] 
Dilute cough-cold products  
 
Ion pairing  ODS UV  
  
Lau et al. 1989 [36] 
Human serum Deproteinizing  Ion pairing  ODS FLU 
 
5 Yamaguchi et al. 1994 [37] 
Human serum SPE (phenyl) Ion pairing  C18  EC  
 
0.35 Vuma et al. 1995 [22] 
Human plasma  SPE (WCX) Ion pairing  ODS EC  
 
2 Gumbhir et al. 1996 [23] 
Human aqueous humor 
 
Ion pairing  CN UV  
 
61 Galmier et al. 2000 [25] 
Extraction from capsules  
  
PEG UV  120 400 Garc´ıa et al. 2002 [26] 
Extraction from capsules and sachets 
   
UV  120 
 
Marı´n et al. 2002 [38] 
Extraction from capsules  
  
PEG UV  
 
2780 Marı´n et al. 2004 [27] 
Water with the ion-pairing reagents Ion-pairing agent  
 
C18  MS 
  
Gao et al. 2005 [24] 
Extraction from sachets 
  
CN UV  4.6 15.3 Olmo et al. 2005 [28] 
0.9% Sodium chloride injection 
  
C18  UV  
  
Kiser et al. 2007 [39] 
Human plasma  SPE (C18) 
 
PFP MS 
 
0.051 Pt´aˇcek et al. 2007 [29] 
Dilute syrup  
 
Ion pairing  C8 UV  
  
Amer et al. 2008 [40] 
Extraction from sachets 
 
Ion pairing  C18  FLU 60 200 Dousa et al. 2010 [30] 
Extraction from sachets 
 
HILIC HILIC FLU 70 230 Dousa et al. 2010 [30] 
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1.5 PHARMACOKINETICS OF PHENYLEPHRINE IN HUMANS 
According to the literature, only a few studies have been conducted to investigate the PK 
properties of PE in humans. Two papers published by Bogner et al. and Cavallito et al. compared 
the plasma concentration-time profiles and urinary excretion of radio-labeled PE after PE 
hydrochloride (immediate-release tablet) and PE tannate (sustained-release tablet) which were 
orally administered to subjects [41, 42]. The disadvantage is that the measurement of total 
radioactivity cannot separate the parent drug from its metabolites in plasma and urine. 
Furthermore, PE hydrochloride and PE tannate were labeled randomly by exposure to tritium gas, 
which adds to the complexity of the radioactive forms in plasma and urine [41, 42]. Both studies 
conclude that the sustained-release dosage form maintains plasma radioactivity levels longer 
than the immediate-release dosage form [41, 42]. Another analytical article determined the serum 
level of the combination of parent and conjugated PE (after acidic hydrolysis) by HPLC with a 
FLU detector [37]. The pilot PK study with this acidic hydrolysis method was excluded for 
further PK analysis because the concentration represents the combination of PE and its 
conjugates.  
Other clinical studies which quantitatively detected parent PE following a single dose are 
listed in Table 1.2. The plasma concentration-time profiles from the figures in these papers were 
obtained by the software DataThief III (Version 1.6). The PK parameters were calculated by a 
non-compartmental PK analysis. Area under the plasma drug concentration-time curve (AUC0-∞) 
and area under the moment curve (AUMC0-∞) were estimated by a linear trapezoidal method. 
Assuming the conjugates only eliminated by urinary excretion, the conjugation clearance (CLcon) 
was estimated by the amount of dose recovered in urine as conjugates divided by AUC0-∞.  
Assuming 3-hydroxymandelic acid only eliminated by urinary excretion, the oxidative 
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deamination clearance (CLmao) was estimated by the amount of dose recovered in urine as 3-
hydroxymandelic acid divided by AUC0-∞. 
Hengstmann et al. measured the total radioactivity and separated free PE and its metabolites 
by column chromatography, solvent extraction, and TLC [19]. The sensitivity and specificity of 
these assays were not evaluated and could bring problems to the validity and reliability of the 
data and furthermore the PK parameters.  
Later on, advanced technology like HPLC with EC detector and liquid chromatography-mass 
spectrometry (LC-MS/MS) was introduced to improve the sensitivity and specificity of PE 
analysis in clinical trials [29]. The variation in the bioanalytic methods may explain the 
difference in the PK parameters in these studies. The data from different studies with different 
assays are not comparable.    
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Table 1.2. Pharmacokinetic Parameters of Phenylephrine in Clinical Trials  
 
AUC0-∞: area under the plasma drug concentration-time curve; AUCextrap: extrapolated AUC 
from last point to infinity; AUMC0-∞: area under the moment curve; Cmax: observed peak 
concentration; Tmax: time at observed peak concentration; t1/2, term: terminal half-life; CLtot: total 
clearance; CLren: renal clearance; CLcon: conjugation clearance; CLmao: oxidative deamination 
clearance; Vdpss: volume of distribution at pseudo-steady-state; Vdss: volume of distribution at 
steady-state; MRT: systemic mean residence time; MAT: mean absorption time; ka: absorption 
rate constant; Foral: oral bioavailability. The parameters with asterisk (AUC0-∞, AUCextrap, 
AUCextrap/AUC0-∞, AUMC0-∞, t1/2, term, CLtot, CLren, CLcon, CLmao, Vdpss, Vdss, MRT, MAT, ka, and 
Foral) were determined from the published images and text as described. Therefore, values differ 
from those reported in the articles. 
 
 
 
 
 
Formulation  
Intravenous 
Solution  
Oral 
Solution 
IR Tablet 
Oral 
Solution 
IR Tablet 
Dose as PE base (mg)  0.842 0.986 8.21 16.4 10.0 
*AUC0-∞ (ng*min/mL) 339 182 108  
  
*AUCextrap (ng*min/mL) 42 30 6  
  
*AUCextrap/AUC0-∞ (%) 12% 16% 6%  
  
*AUMC0-∞ (ng*min
2
/mL) 67880 38167 8073 
 
  
Cmax (ng/mL)   0.9 1.8 3.1 0.6 
Tmax (min)   75 36 40 30 
*t1/2, term (min) 181 130 78  
  
*CLtot (mL/min) 2486      
  
*CLren (mL/min) 398 141    
  
*CLcon (mL/min) 206 2474    
  
*CLmao (mL/min) 1414 1310    
  
*Vdpss (L) 648      
  
*Vdss (L) 478      
  
*MRT (min) 192 210 75 
 
  
*MAT (min) 
 
17   
 
  
*ka (min
-1
) 
 
0.06   
 
  
*Foral  
46% 
   
Reference 
Hengstmann et al. 
1982 [19] 
Hengstmann et al. 
1982 [19] 
Ptacek et al. 
2007[29] 
Vuma et al. 1996 
[22] 
Schering-Plough 
Corporation 2007 
[43] 
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The plasma protein binding for PE is not available in the literature. But it was reported that 
the binding to human serum albumin and plasma for etilefrine (ET) is 8.5 ± 2.6% and 23 ± 4%, 
respectively, in the concentration range of 0.4 - 46 ng/mL [44]. ET has a structure similar to PE. 
PE is expected to have similar plasma protein binding. There is not enough information from the 
above data to determine whether PE exhibits linear or non-linear pharmacokinetics. Peak plasma 
levels showed inter-study variability, and were found between 30 and 75 min [19, 22, 29, 43].  
Both the CLren after intravenous and oral administration were larger than the product of 
glomerular filtration rate by the unbound fraction of PE in plasma, which indicates net renal 
tubular secretion. The non-renal clearance was higher than hepatic blood flow of 1500 mL/min, 
which indicates the contribution of other organs to the extra-hepatic clearance. CLmao was similar 
after intravenous and oral administration. CLcon was much higher after oral dose than that after 
intravenous dose. This indicates conjugation plays an important role in pre-systemic metabolism 
of PE. The volume of distribution at steady state exceeded total body water. This suggests the 
extensive distribution of PE in certain organs/tissues, possibly due to transporter-mediated 
uptake into tissues or extensive tissue binding. PE is ionized at the physiological pH. It is 
difficult for PE to penetrate into the tissues by passive diffusion. It is probably transferred into 
the tissues by active transporters. The structure of PE is similar to norepinephrine and dopamine, 
which are taken into neurons or extra-neuronal tissues by transporters like the norepinephrine 
transporter, dopamine transporter and organic cation transporters [45-47]. The distribution of PE 
into tissues may also be mediated by such transporters, potentially resulting in large volume of 
distribution at steady state.  
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1.6 LOW BIOAVAILABILITY AND EXTENSIVE PRE-SYSTEMIC METABOLISM 
PE is almost completely absorbed with 95.3% of the oral dose at 24.6 mg recovered in urine 
[20]. Another study found 79.5% of the oral dose at 0.986 mg recovered in urine [19]. The rest 
could possibly be excreted by bilinary excretion and recover in feces. Since PE has high 
solubility and high permeability, it is classified as Biopharmaceutics Classification System Class 
I compound. The oral bioavailability (Foral) of PE was determined as 38 ± 9% (mean ± SD, 
recalculated based on the individual data in the paper published by Hengstmann et al.) [19]. The 
low oral bioavailability of PE is likely due to pre-systemic metabolism. Urine contained 2.6% 
free PE, 45.7% conjugated PE, and 24.2% 3-hydroxymandelic acid after 0.986 mg oral dose 
[19]. Compared with the urinary recovery after 0.842 mg intravenous dose containing 16% free 
PE, 8.3% conjugated PE, and 56.9% 3-hydroxymandelic acid, it seems more PE undergoes 
conjugation by oral route and more PE converts to 3-hydroxymandelic acid by intravenous route 
[19]. The total excretion of administered dose after oral and intravenous administration was 
calculated by cumulative urinary excretion of 
3
H-activity in Table 1.3, which is larger than the 
sum of the dose excreted as parent PE and each identified metabolite [19]. This indicates there 
are some unidentified metabolites recovered in urine. Another study detected four metabolites in 
urine after oral administration of 24.6 mg PE over 8 hrs, which were 30% 3-hydroxymandelic 
acid, 6% 3-hydroxyphenylglycol sulfate, 47% PE sulfate, and 12% PE glucuronide (Table 1.3) 
[20].  These results are consistent with those after 0.986 mg oral administration. The major 
routes for oral PE metabolism in humans are sulfation and oxidative deamination. After 
inhalation of 10, 24, and 34 mg PE by three subjects over 9 hrs, the components recovered in the 
urine were 24% 3-hydroxymandelic acid, 6% 3-hydroxyphenylglycol sulfate, 56% PE sulfate, 
and 5% PE glucuronide, which were similar to the oral route (Table 1.3) [20].  This indicates 
  
12 
 
that the lung also has extensive sulfation activity, which has been reported in the literature [48-
50]. The proposed metabolic pathway for PE is shown in Figure 1.2. 
The intestine may play an important role in pre-systemic PE metabolism. PE is a substrate of 
SULT1A3, which is highly expressed in human intestine, but absent in human and rodent liver 
[51]. In the past years, researchers paid more attention to the first-pass metabolism in the liver 
[52, 53]. Recently, the interest in pre-systemic intestinal metabolism is increasing [52, 53]. The 
intestinal availability of salbutamol is even less than the hepatic availability [52, 53]. Salbutamol 
has a structure similar to PE and mainly undergoes sulfation, which suggests intestinal 
metabolism is probably important for pre-systemic PE metabolism.  
There are differences in metabolism of PE across animal species. After intraperitoneal 
injection of 250 μg PE into rats, 7% free PE, 5% 3-hydroxymandelic acid, 35% 3-
hydroxyphenylglycol sulfate, 5% PE sulfate, and 4% PE glucuronide recovered in urine (Table 
1.3) [20]. The metabolism of PE in rats is highly different from that in human.  The evidence of 
the species difference of sulfation can also be found in the literature [54-57]. The species 
difference in sulfation is associated with the difference in gene and enzyme expression levels. 
Homologous sequences for SULT1A3 haven’t been found in other species [58]. This indicates 
that animal models such as rat may not be a good choice for studying PE metabolism in humans. 
Thus, animal models such as rat have been excluded from the current study.  
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Table 1.3. Urinary Excretion of Phenylephrine Metabolites as Percentage of Administered Dose  
 
Urinary Excretion of Administered Dose (%) 
 
Human Rat 
Route of administration  
Intravenous  
Injection 
Oral Solution Oral Tablet Inhalation  
Intraperitoneal 
Injection 
Subject  3 10 3 3 3 
Dose as PE base  0.842 mg 0.986 mg 24.6 mg  10, 24, 34 mg 250 μg 
Urine collecting time 48 hrs 48 hrs 24 hrs 24 hrs 24 hrs 
PE sulfate  8.3  45.7  47 56 5.0 
PE glucuronide    12 5 4.0 
3-Hydroxymandelic acid  56.9  24.2  30 24 5.0 
3-Hydroxyphenylglycol sulfate  Not detected  Not detected  6 6 35.0 
Free PE  16.0  2.6  0.3  1.5 7.0 
Total excretion of administered dose    86.3  79.5  95.3  92.5 56.0 
Reference 
Hengstmann et al. 
1982 [19] 
Hengstmann et al. 
1982 [19]  
Ibrahim et al. 
1983 [20]    
Ibrahim et al. 
1983 [20]    
Ibrahim et al. 
1983 [20]    
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Figure 1.2. Proposed Metabolic Pathways of Phenylephrine 
 
UGT: uridine 5’-diphospho-glucuronosyltransferase; SULT: sulfotransferase; MAO: monoamine oxidase;                                    
ALDH: aldehyde dehydrogenase; AR: aldehyde reductase.                                               
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1.7 PREDOMINANT METABOLIC PATHWAYS: SULFATION AND OXIDATIVE 
DEAMINATION 
Sulfation and oxidative deamination are the two predominant metabolic pathways for PE 
[20]. Sulfation is an important conjugation reaction, which belongs to Phase II metabolism [51]. 
A sulfonate group is transferred from the cofactor 3’-phosphoadenosine-5’-phosphosulfate 
(PAPS) to hydroxyl or amino groups of the compounds under the catalysis of SULTs [51].  This 
reaction leads to more water-soluble metabolites, which facilitates excretion [51]. In general, 
sulfation is a high-affinity, low-capacity reaction compared to uridine 5’-diphospho-
glucuronosyltransferase (UGT) [59].  The total amount of PAPS in the whole liver can be 
consumed in less than 2 min [59]. Substrate inhibition is very common for SULTs [60-63]. 
SULT has many isoforms in humans, most of which have substrate overlap. SULT activities are 
higher in the small intestine than in the stomach or colon. However, the activities in different 
segments of small intestine show differences [60]. SULTs are also expressed in the liver and the 
level of phenol SULT in the liver shows inter-individual variation [51]. Model substrates were 
used to test the SULT activities in the liver among various species (human, monkey, dog, rabbit, 
rat, mouse, guinea pig, and hamster), and the results show large species differences [51]. In rat, 
mouse, and rabbit only one form of ST1A (phenol SULT) has been reported so far [64].  
PE is not a substrate of SULT1A1 when it was tested at 10 mM [65]. Monoamine-sulfating 
phenol transferase SULT1A3 was reported to be involved in the sulfation of PE [65]. SULT1A3 
prefers bioamines such as PE, catecholamine and dopamine [66]. SULT1A3 is almost negligible 
in the liver, but has high expression levels in the colon and jejunum [67, 68].  Single nucleotide 
polymorphisms have been found for SULT1A3, but this does not significantly affect the 
Michaelis-Menten constant (Km) value for its typical substrate and cofactor PAPS [58]. 
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Oxidative deamination by MAO is a type of Phase I metabolism. MAO exists in almost all 
the tissues and is located in the outer membrane of mitochondria [69]. It can oxidize primary 
aliphatic and aromatic amines, as well as some secondary and tertiary amines [69]. Flavin 
adenine dinucleotide is the cofactor [69]. There are two isoforms of MAO: MAO-A and MAO-B 
[69]. Synephrine, a regioisomer of PE, is metabolized by both types of MAO and mainly by 
MAO-A [70]. Dopamine, which has structural similarity with PE, is metabolized by both MAO-
A and MAO-B [71, 72].   
1.8 COMMON APPROACHES TO IMPROVE ORAL BIOAVAILABILITY 
In order to improve oral bioavailability, there are several common approaches in the 
literature such as modified formulations, pro-drugs and inhibiting pre-systemic metabolism by 
co-administration of enzyme inhibitors. Modified formulations with chitosan microsphere or 
cyclodextrin complex can only increase the solubility of poorly soluble drugs (unlike PE), but 
cannot inhibit the pre-systemic metabolism of the drug [73, 74]. So when the drug is absorbed in 
the intestine and then goes through the portal vein into the liver, it still gets metabolized, which 
lowers the oral bioavailability. These new formulations could not solve the problem of low oral 
bioavailability due to extensive pre-systemic metabolism. Pro-drugs can be synthesized to 
protect groups on the drug molecule which are easily metabolized by first-pass metabolism. But 
since the pro-drug would be a new chemical entity, the toxicity would be unknown and would 
need extensive and expensive investigation. The stability of the pro-drug in gastric fluid and 
blood is also unknown. Stability studies have to be done to prove it is an effective pro-drug, 
which is very resistant to the gastric fluid and can convert to the active drug in plasma. The effort 
also has to be put to synthesize the drug. Co-administration of enzyme inhibitors with the drug 
orally can inhibit pre-systemic metabolism of the drug and increase its oral bioavailability. 
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Ritonavir is used as an inhibitor of pre-systemic metabolism of lopinavir [75]. Among these 
approaches, co-administration of the inhibitors for pre-systemic metabolism is the most 
appropriate one for drugs with extensive pre-systemic metabolism, which will be discussed in the 
next section. 
1.9 THE STRATEGY TO INCREASE ORAL BIOAVAILABILITY OF 
PHENYLEPHRINE: INHIBITION OF PRE-SYSTEMIC SULFATION  
The efficacy of PE, the most commonly used over-the-counter oral nasal decongestant, is 
questioned because of its low and variable oral bioavailability, which appears to be due to its 
extensive pre-systemic metabolism [3, 19]. If the pre-systemic metabolism of PE can be 
inhibited, the variability of the oral bioavailability for PE can be reduced and the oral 
bioavailability of PE can be increased. Finally the efficacy can be better realized. As described 
above, more PE is conjugated mainly as sulfate by the oral route (45.7%) than that by the 
intravenous route (8.3%) [19]. Less PE is biotransformed to 3-hydroxymandelic acid by the oral 
route (24.2%) than after the intravenous route (56.9%) [19]. This indicates that sulfation may 
play a significant role in pre-systemic metabolism of PE. If the major pre-systemic metabolic 
pathway, i.e., sulfation, can be inhibited, the oral bioavailability of PE may be improved. The 
sulfation of PE occurs at its phenolic group, which is a common structural feature for many 
SULT substrates [51]. The compounds with phenolic groups have similar structures as PE and 
may share affinity for the same SULT isoforms with PE, which obtain the potential to inhibit 
sulfation of PE. Therefore, co-administration of phenolic compounds with PE can be an 
appropriate strategy to inhibit the pre-systemic sulfation of the drug.   
Considering safety concerns, phenolic compounds from FDA’s “GRAS” list, EAFUS, or 
dietary supplements are the first choice of potential inhibitors. GRAS substances are compounds 
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generally recognized as safe. Experts have already evaluated the safety of these compounds from 
many aspects such as systemic exposure, metabolism, pharmacokinetics and toxicology. For 
toxicology, many aspects are considered such as carcinogenicity, genotoxicity, reproductive 
toxicity, and the median lethal dose in animals. Adequate scientific information is available to 
prove their safety as food additives. EAFUS lists the substances used as food additives, some of 
which are included in FDA’s “GRAS” list. The substances listed in EAFUS can be directly 
added into food. Dietary supplements are basically vitamins, minerals, botanicals, herbs, herbal 
extracts, amino acids, and various other natural compounds, most of which have been used for 
many years without reported safety issues. Many successful examples of applying dietary 
compounds to inhibit metabolism and finally improve the oral bioavailability can be found in the 
literature: when 2 g curcumin was orally administered alone to human subjects, the plasma 
concentration of the parent compound was very low or even below LLOQ [76]. But when orally 
co-administered with 20 mg piperine, the plasma concentration of curcumin was significantly 
increased between 0.25 and 1 hr. The oral bioavailability was increased by 20-fold by piperine 
[76]. Piperine is used as a feasible absorption/bioavailability enhancer for some compounds 
probably by improving absorption and decreasing metabolism [77]. Piperine was also found to 
enhance the plasma concentration and the oral bioavailability of resveratrol [78]. Co-
administration of biochanin A with quercetin and (-)-epigallocatechin-3-gallate lead to an 
increase in the oral bioavailability of biochanin A in rats [79].  Thus, co-administration of 
phenolic compounds from FDA’s “GRAS” list, EAFUS, or dietary supplements with PE could 
be a safe way to inhibit pre-systemic metabolism of PE. 
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1.10 SUMMARY 
PE is widely used as oral nasal decongestant. It has been used safely for many years. But the 
efficacy of PE is controversial due to its low and variable oral bioavailability. The extensive pre-
systemic metabolism contributes to the low and variable oral bioavailability of PE. Sulfation 
plays a very important role in pre-systemic metabolism of PE. The sulfation of PE occurs at its 
phenolic group, which is the preferred structural feature of many SULT substrates. Compounds 
with phenolic groups have similar structures to PE, which may share the same SULT isoforms 
with PE and have the potential to inhibit PE sulfation. Considering safety concerns for oral 
consumption, phenolic compounds from FDA’s “GRAS” list, EAFUS, or dietary supplements 
are the first choice of potential inhibitors to inhibit the pre-systemic sulfation of PE. The primary 
side effect of PE is hypertension. Since MAO inhibitors may increase the risk of hypertension, 
they should not be taken with PE. Therefore, as the co-administered phenolic compounds to 
improve the oral bioavailability of PE, the inhibitory effects of these compounds on MAO are 
not desired. The disposition scheme for research project goals is shown in Figure 1.3.  
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Figure 1.3. Disposition Scheme for Research Project Goals  
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CHAPTER 2 
 
OBJECTIVE AND SPECIFIC AIMS 
 
 
 
 
2.1 OBJECTIVE AND HYPOTHESIS 
2.1.1 Objective 
The objective of this project is to test the feasibility of using phenolic dietary compounds 
from FDA’s “GRAS” list, EAFUS, or dietary supplements, as excipients to increase the oral 
bioavailability of PE: 1) Investigate whether phenolic dietary compounds inhibit the metabolism 
of PE using the in vitro LS180 cell model; 2) Investigate whether phenolic dietary compounds 
have any in vitro inhibitory effects on human MAO-A/B.  
2.1.2 Hypothesis 
Phenolic dietary compounds can inhibit pre-systemic sulfation of PE to improve its oral 
bioavailability, preferably with no or less inhibition on MAO metabolic activities.  
2.2 SPECIFIC AIMS 
2.2.1 Specific Aim I 
Test phenolic dietary compounds for metabolic inhibition of PE in LS180 cell model via 
monitoring of PE disappearance. 
1) Characterize the sulfation activity in LS180 cells with a model compound, 1-naphthol.   
2) Develop an HPLC method to determine PE in both the extracellular incubation buffer 
media and LS180 cell lysates.  
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3) Determine the time- and concentration-dependent PE metabolism in LS180 cell model.  
4) Determine the extent of PE disappearance in the presence of phenolic dietary compounds. 
2.2.2 Specific Aim II 
Chemically synthesize and characterize PE sulfate and ET sulfate for quantitative analysis of 
PE sulfate in LS180 cell model by LC-MS/MS. 
1) Design the routes for chemical synthesis and synthesize PE sulfate as well as ET sulfate 
with “protecting group” strategy. 
2) Identify and characterize PE sulfate and ET sulfate by nuclear magnetic resonance (NMR) 
and MS and test the purity of these newly synthesized compounds by HPLC. 
3) Chemically hydrolyze PE sulfate and ET sulfate to determine their original 
concentrations. 
4) Develop an LC-MS/MS method for simultaneous quantitative analysis of PE, PE sulfate, 
and 3-hydroxymandelic acid, and apply it to a preliminary sulfation inhibition study in 
LS180 cells. 
2.2.3 Specific Aim III 
Test selected phenolic compounds for inhibitory activities against MAO-A/B using 
kynuramine as a marker substrate, and determine their IC50 values.  
1) Develop and validate an HPLC method with FLU and UV detection for simultaneous 
determination of kynuramine and its oxidative deamination product, 4-hydroxyquinoline. 
2) Characterize the time- and MAO-A/B concentration-dependent kynuramine oxidative 
deamination and determine the Km values.  
3) Test the phenolic dietary compounds for MAO-A/B metabolic inhibition of kynuramine 
and determine the IC50 values.  
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CHAPTER 3 
 
SCREENING POTENTIAL INHIBITORS FOR PRE-SYSTEMIC SULFATION OF 
PHENYLEPHRINE WITH LS180 CELL MODEL 
 
 
 
 
3.1 INTRODUCTION 
According to the sulfation activities of PE with SULT recombinant enzymes, PE appears to 
be a substrate of SULT1A3 but not SULT1A1 [51]. It is not now clear however whether other 
forms of SULT also contribute to the sulfation of PE. As mentioned earlier, SULT1A3 is 
expressed in humans but its homologous sequences have not been found in other species [58], 
and thus, animal models are not appropriate to study PE sulfation and its inhibition.  In humans, 
SULT1A3 is very specific for exogenous and endogenous monoamine phenols and highly 
expressed in the jejunum and colon, but absent in the liver [67]. Catecholamine dopamine, which 
has structural similarities with PE, is a typical substrate for SULT1A3 with Km value of 2.9 μM 
or 9.7 μM reported in the literature [61, 65]. Dopamine has a much lower affinity towards 
SULT1A1 [65].  
Considering the safety issue, phenolic compounds are from FDA’s “GRAS” list, EAFUS, or 
dietary supplements. GRAS substances are compounds generally recognized as safe. Experts 
have already evaluated the safety of these compounds from many aspects such as exposure, 
metabolism, pharmacokinetics and toxicology. Adequate scientific information is available to 
improve their safety as food additives. EAFUS listed the substances used as food additives, some 
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of which are included in FDA’s “GRAS” list. The substances from EAFUS can be directly added 
into food. Dietary supplements are basically vitamins, minerals, botanicals, herbs, and amino 
acids, most of which have been used for many years with no safety problems.  Therefore 
phenolic compounds, which have FDA’s “GRAS” list, EAFUS, or dietary supplements status, 
are the first choice as the co-administered substances for PE.  
3.2 MATERIALS AND METHODS 
3.2.1 Chemicals and Reagents 
Curcumin (mixture of curcumin, demethoxycurcumin and bisdemethoxycurcumin) and 
methylparaben, and quercetin hydrate were purchased from Acros Organics (Morris Plains, NJ). 
Ethyl vanillin, 1-naphthol, naringin hydrate, zingerone were purchased from Alfa Aesar 
(Heysham, Lancs, England). Eugenol was purchased from TCI-EP (Tokyo, Japan). Guaiacol, 
isoeugenol, propylparaben, and vanillin were purchased from TCI America (Portland, OR). L-
Ascorbic acid was purchased from Sigma-Aldrich (St. Louis, MO). L-phenylephrine 
hydrochloride was purchased from MP Biomedicals, LLC. (Solon, Ohio). 1-Naphthyl sulfate 
potassium salt was purchased from Research Organics (Cleveland, OH). Pterostilbene was 
purchased from ChromaDex (Irvine, CA). Resveratrol was purchased from Beta Pharma, Inc. 
(New Haven, CT).    
Acetic acid, glacial was purchased from Fisher Scientific (Fair Lawn, NJ). Methanol was 
purchased from Avantor Performance Materials, Inc. (Center Valley, PA). 
High glucose Dulbecco’s modified Eagle’s medium (DMEM) and non-essential amino acids 
solution (100X) were purchased from HyClone, Laboratories, Inc., Thermo Scientific (South 
Logan, Utah).  
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3.2.2 Apparatus  
An Alltima C18 column (250 × 4.6 mm, 5 μm) was purchased from Grace Davison 
Discovery Sciences (Deerfield, IL).  
A Hypersil phenyl column (150 × 2 mm, 3 μm) was purchased from Meta Chem 
Technologies, Inc. (Torrance, CA).  
Savant refrigerated vapor trap was purchased from Thermo Scientific (Waltham, MA).  
The chromatographic experiments were conducted by HPLC systems including Waters 2695 
separation module, Waters 2487 dual λ absorbance detector, and Waters 2475 multi λ FLU 
detector (Waters Corporation, Milford, MA). 
3.2.3 Screening of Potential Inhibitors 
Potential inhibitors were selected by two major criteria: structural characteristics and 
potential for oral consumption. All potential inhibitors have phenolic groups like PE. The 
structures of potential inhibitors are shown in Figure 3.1. They are from FDA’s “GRAS” list, 
EAFUS, or dietary supplements. Among them curcumin, guaiacol, isoeugenol, methylparaben, 
naringin, propylparaben, pterostilbene, quercetin, resveratrol, vanillin, and zingerone are 
substrates of SULTs, which were reported in literature as shown in Table 3.2. The SULT activity 
can usually be inhibited by substrates or their analogues. Since these compounds are substrates 
of SULTs, they are consumed, and the products are released from the enzyme. It is highly likely 
for them to be reversible inhibitors for SULTs, since mechanism-based inhibition has not been 
observed with these dietary compounds in the literature. Curcumin was shown to inhibit 
acetaminophen sulfation in LS180 cells and human liver cytosol with IC50 of 2.6 ± 0.4 μM and 
5.9 ± 0.4 μM, respectively [80]. Quercetin inhibited sulfation of several compounds such as 4-
nitrophenol, dopamine, salbutamol, minoxidil and acetaminophen in duodenum and liver cytosol 
  
26 
 
[81]. The IC50 for quercetin inhibition of 4-nitrophenol sulfation in liver cytosol was 0.10 ± 0.03 
μM. The type of inhibition on partially purified SULT1A1 was noncompetitive inhibition with 
the dissociation constant for an inhibitor of enzyme (Ki) of 0.1 μM [82]. Methylparaben and 
propylparaben were found to inhibit estradiol sulfation [83]. Naringin significantly inhibited 
human recombinant SULT1A3 but not SULT1A1 [84]. Vanillin strongly inhibited the activity of 
SULT1A3 [85]. Vanillin inhibited 17α-ethinyloestradiol sulfation in human liver cytosol with 
IC50 of 1.3 μM. The type of inhibition with vanillin was noncompetitive inhibition [85]. 
The chemical and PK properties of potential inhibitors are shown in Table 3.1 and Table 3.2, 
respectively. This list of potential inhibitors does not have any amines, which could be typical 
MAO substrates. The molecular weights are calculated with the 1997 IUPAC atomic weights. 
The values of logD, molar solubility, logP, and pKa are predicted by Advanced Chemistry 
Development/Labs softwares. These predicted values are determined based on the database of 
accurate experimental values of a large amount of compounds. Most phenolic dietary compounds 
are unionized at the physiological pH, like intestinal pH and plasma pH, except naringin and 
quercetin. Most phenolic dietary compounds probably cross the cell membrane by passive 
diffusion based on their chemical properties. It is less possible for these phenolic dietary 
compounds to interact with the transporters responsible for PE uptake and inhibit PE uptake. As 
seen in the tables, potential inhibitors are small molecules, most of which are substrates for 
SULTs. In Table 3.2, the fraction of the oral dose absorbed (Fa) for most potential inhibitors 
were determined by the percentage of the dose recovered in urine in animals or humans in the 
literature. According to the available data, potential inhibitors have moderate to high Fa. The data 
of Foral for potential inhibitors are limited and predictions were not performed. The enzymes 
responsible for metabolism of these phenolic compounds are also listed in Table 3.2.   
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Figure 3.1. Structures of Potential SULT Inhibitors Selected from FDA’s “GRAS” List, 
EAFUS, or Dietary Compounds 
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Table 3.1. Chemical Properties of Potential Inhibitors [8] 
Compound  logD (25 
o
C, pH 7) Solubility (25 
o
C, pH 7) logP (25 
o
C) 
Molecular 
Weight 
pKa (25 
o
C) 
Curcumin 3.02 1.4E-4 mol/L 3.071 ± 0.444 368.38 Most acidic 8.11 ± 0.46 
Ethylvanillin 1.67 0.011 mol/L 1.718 ± 0.272 166.17 Most acidic 7.91 ± 0.18 
Eugenol 2.40 0.011 mol/L 2.403 ± 0.236 164.20 Most acidic 10.29 ± 0.18 
Guaiacol  1.34 0.086 mol/L 1.341 ± 0.220 124.14 Most acidic 9.97 ± 0.10 
Isoeugenol  3.08 7.3E-3 mol/L 3.081 ± 0.248 164.20 Most acidic 10.10 ± 0.31 
Methylparaben  1.86 0.037 mol/L 1.882 ± 0.224 152.15 Most acidic 8.31 ± 0.13 
Naringin -0.42 1.9E-4 mol/L -0.198 ± 0.791 580.53 Most acidic 7.17 ± 0.40 
Propyl gallate 1.72 0.037 mol/L 1.779 ± 0.331 212.20 Most acidic 7.94 ± 0.25 
Propylparaben  2.88 6.5E-3 mol/L 2.901 ± 0.224 180.20 Most acidic 8.23 ± 0.15 
Pterostilbene 4.06 2.7E-4 mol/L 4.056 ± 0.261 256.30 Most acidic 9.96 ± 0.26 
Quercetin  1.08 6.3E-3 mol/L 1.989 ± 1.075 302.24 Most acidic 6.31 ± 0.40 
Trans-resveratrol  3.02 9.4E-5 mol/L 3.024 ± 0.267 228.24 Most acidic 9.22 ± 0.10 
Vanillin 1.14 0.028 mol/L 1.208 ± 0.272 152.15 Most acidic 7.78 ± 0.18 
Zingerone  1.17 0.024 mol/L 1.168 ± 0.237 194.23 Most acidic 10.03 ± 0.20 
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Table 3.2. Pharmacokinetic Properties of Potential Inhibitors  
Compound Foral Fa Metabolite Metabolizing Enzyme Dose Range 
Curcumin  60%* [86] 
glucuronide, sulfate [87-89], 
tetrahydrocurcumin [89], 
hexahydrocurcumin, 
hexahydrocurcuminol [88, 89] 
SULT1A1, SULT1A3,  
alcohol dehydrogenase [89] 
0 - 1 mg/kg  body  
weight/day [90], not toxic in 
humans at 8 g/day oral dose 
for 3 months [91], 4 g, 6 g, 8 
g [91], 450 - 800 mg (dietary 
supplement) 
Ethylvanillin   
3-ethoxy-4-hydroxybenzoic acid, 3-
ethoxy-4-hydroxymandelic acid [92] 
 0.143 mg [92] 
Eugenol  95% [93] 
conjugates of eugenol, 4-hydroxy-3-
methoxyphenyl-propane, cir- and trans-
isoeugenol, 3-(4-hydroxy-3-
methoxyphenyl)-propylene-1,2-oxide, 
3-(4-hydroxy-3-methoxyphenyl)-
propane-1,2-diol, 3-(4-hydroxy-3-
methoxy-phenyl)-propionic acid [93] 
  
Guaiacol  45% [94] glucuronide, sulfate [94]  
54 mg [94, 95] 
Isoeugenol  85%* [96] glucuronide*, sulfate* [96]   
Methylparaben   glucuronide, sulfate [97] 
UGT1A1, UGT1A6, 
UGT1A7, UGT1A8, 
UGT1A9, UGT1A10, 
UGT2B4, UGT2B7, 
UGT2B15, UGT2B17 [97] 
≤ 0.1% in food [98] 
 
Naringin   
naringenin (human intestinal bacteria) 
[99], naringenin glucuronide, naringenin 
sulfate 
 16.2 mg/kg [100] 
 
Propyl gallate 
 
 
79%* 
[101] 
 
4-methoxygallic acid, pyrogallol, 2-
methoxypyrogallol, gallic  acid, 
pyrogallol glucuronide, 4-methoxygallic 
acid glucuronide, 2-methoxypyrogallol 
glucuronide* [101] 
 
 
≤ 0.02% of the fat or oil 
content [98] 
Propylparaben  96%* p-hydroxybenzoic acid [102], carboxylesterase [102] ≤ 0.1% in food [98] 
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[102] glucuronides, sulfate, hippuric acid of p-
hydroxybenzoic acid* [103] 
Pterostilbene 
12.5%* 
[104], 
80%* 
[105] 
 glucuronide* [105, 106], sulfate* [105]  
50 - 250 mg (dietary 
supplement) 
Quercetin  
36 - 53% 
[107] 
65 – 81% 
[108] 
3-glucuronide, 3’-sulfate [109-111],  3’-
methylquercetin-3-glucuronide [111] 
catechol-O-methyltransferase 
[112] 
8 mg, 20 mg, 50 mg [113], 
100 mg (i.v.) [114], 100 -
1575 mg (i.v.) [115], 500 mg 
(dietary supplement) 
Trans-
resveratrol 
 71% [116] 
3-glucuronide, 4’-glucuronide [117, 
118], 3-sulfate [119, 120], 4’-sulfate, 
3,4’-disulfate [120] 
SULT1A1, SULT1A2, 
SULT1A3, SULT1E1 [120], 
UGT1A1, UGT1A6, UGT 
1A7, UGT 1A9, UGT1A10 
[118] 
25 mg, 50 mg, 100 mg, 150 
mg [121], 0.5 g, 1.0 g, 2.5 g, 
5.0 g [119], 100 - 700 mg 
(dietary supplement) 
Vanillin  
94%* 
[122] 
vanillin, vanillyl alcohol, vanillic acid, 
vanilloylglycine, catechol, 4-
methylcatechol, guaiacol, 4-
methylguaiacol, protocatechuic acid 
(free and conjugated forms)* [122], 
sulfate [85, 123] 
SULT1A3 [85, 123]  
Zingerone  
95%* 
[124] 
glucuronide*, sulfate* [124]  10 mg (dietary supplement) 
 
Fa: fraction of the oral dose absorbed; Foral: oral bioavailability; UGT: uridine 5’-diphospho-glucuronosyltransferase; SULT: 
sulfotransferase. The asterisk indicates the data are from animal studies. 
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3.2.4 LS180 Cell Culture  
LS180 cells were grown in DMEM with high glucose (4.5 g/L), 10% FBS, and 1% non-
essential amino acid at 37 
o
C with 5% CO2. The cells were fed every other day. They grew 
horizontally, and never reach 100% confluence if seeded at a low density. The cell culture 
medium was continuously increased from 12 to 25 mL in 75 cm
2
 flask to keep pace with 
increasing metabolic demands of the growing cells.   
When LS180 cells were sub-cultured, old medium was removed and the 75 cm
2
 flask was 
filled with 5 mL fresh medium. Since trypsin changes the cell type, it was not used for cell sub-
culture. Instead, cells were gently scraped by a cell scraper. In order to disperse the cells, cells 
were passed through a 23G ×1 needle for 6 times and dispensed to a new flask. Cells were sub-
cultured in 6-7 days with a dilution of 1:10. Cell passage number was between 42 and 60. A new 
vial of LS180 cells was recovered from the liquid nitrogen about every 3 months. 
3.2.5 Characterization of the Sulfation Activity in LS180 Cells 
1-Naphthol has a molecular weight of 144.17. The calculated logP is 2.724 ± 0.189 at 25 
o
C, 
indicating it is a lipophilic compound, and pKa is 9.4 [8]. It is unionized at physiological pH. 1-
Naphthol is a substrate for SULT1A1, SULT1A3, SULT1B1, and SULT1E1, which are the four 
major SULT isoforms in the intestine [67, 68]. SULT1A3 activity is much higher than SULT1A1 
activity when determined at concentrations of 10 and 100 μM 1-naphthol with 13 μM PAP35S 
and 200 ng recombinant protein [123]. The sulfate of 1-naphthol is commercially available from 
Research Organics (Cleveland, OH). Therefore 1-naphthol was used to characterize the sulfation 
activity in LS180 cells. 
LS180 cells were seeded at the concentration of 1.9 × 10
5
 cells/mL in the 12-well plate. The 
experiment was carried out on the 4th day after plating cells. For the linearity study for 
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incubation time, cells were equilibrated with 0.5 mL 10 mM HEPES in Hank’s balanced salt 
solution (HBSS) (pH 7.4) for 20 min and then incubated with 1-naphthol (10 μM) in the 
incubation media for 0 - 2 hrs. After incubation, 0.5 mL 10 mM HEPES in HBSS was removed 
and stored at -80
 o
C until analysis.  The metabolic reactions were quenched by placing the 12-
well plate on ice and quickly rinsing the wells with 1 mL cold (-20 
o
C) methanolic solution (60% 
methanol and 40% 70 mM HEPES (pH 5.5)). The cell extraction of metabolites was carried out 
with 1 mL methanol. Cells were scraped and collected in centrifuge tubes. The suspension was 
mixed for 2 - 3 min and centrifuged at 13000 rpm for 5 min. 800 µL supernatant was collected. 
Each well in the plate was washed with 1 mL methanol twice. The washing solution was 
collected with the supernatant and dried in the vacuum concentrator. The residue was re-
suspended in 35 µL buffer matrix (50% methanol and 50% (5% triethylamine in water adjusted 
to pH 3.0 with acetic acid)). 
1-naphthol and its sulfate in HBSS buffer containing 10 mM HEPES and cell lysates from 
metabolism studies in LS180 cells were analyzed by an HPLC method with an Alltima C18 
column (250 × 4.6 mm, 5 μm) at 40 oC with isocratic elution (50% methanol and 50% (5% 
triethylamine in water adjusted to pH 3.0 with acetic acid)) at the flow rate of 0.75 mL, and 
detected by UV at wavelength of 283 nm. The standard curves for 1-naphthol and its sulfate 
were linear (r
2
 > 0.99) in the concentration range of 0.15 - 50 μM. The experiments were 
repeated three times. 
3.2.6 HPLC Method for Phenylephrine 
PE samples in DMEM containing 1% non-essential amino acid and cell lysates from 
metabolism studies in LS180 cells were analyzed by an HPLC method with a phenyl column 
(150 × 3.2 mm, 5 μm, 55 oC) at the flow rate of 0.75 mL (20% methanol and 80% 1% acetic acid 
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in water) and detected by FLU (excitation 270 nm, emission 305 nm). The standard curves for 
PE in both extracellular buffer and cell lysate were linear from 0.15 to 5000 μM with r2 > 0.99. 
Difference from nominal (DFN) at low (0.3 μM), medium (30 μM), and high (100 μM) 
concentration in extracellular buffer was -3.6%, 0.0%, and 0.0%, respectively. Relative standard 
deviation (RSD) at low (0.3 μM), medium (30 μM), and high (100 μM) concentration in 
extracellular buffer was 13.8%, 1.5%, and 0.1%, respectively. DFN at low (0.3 μM), medium (30 
μM), and high (100 μM) concentration in cell lysate was 4.2%, 3.8%, and -2.6%, respectively. 
RSD at low (0.3 μM), medium (30 μM), and high (100 μM) concentration in cell lysate was 
6.9%, 5.8%, and 4.6%, respectively. 
3.2.7 Linearity of Incubation Time and Concentration-dependent Study 
LS180 cells were seeded at a concentration of 1.9 × 10
5
 cells/mL in the 12-well plate. The 
experiment was carried out on the 4th day after plating the cells. In order to optimize the 
incubation time, cells were incubated with 0.5 mL DMEM containing 1% non-essential amino 
acid (pH 7.4) with PE (50 μM) from 0 to 40 hrs at 37 oC with 5% CO2. For the concentration-
dependent study, the cells were incubated with 0.5 mL DMEM containing 1% non-essential 
amino acid (pH 7.4) with PE covering a wide range of concentrations (1 - 3525 μM) for 18 hrs 
(from the incubation time optimization study) at 37
 o
C with 5% CO2. After incubation, DMEM 
with 1% non-essential amino acid was removed and stored at -80 
o
C until analysis.  The 
metabolic reactions were quenched by placing the 12-well plate on ice and quickly rinsing the 
wells with 1 mL cold (-20 
o
C) methanolic solution (60% methanol and 40% 70 mM HEPES (pH 
5.5)) to avoid non-specific binding. The cell extraction of metabolites was carried out with 1 mL 
methanol. Cells were scraped and collected in centrifuge tubes. The suspension was vortexed for 
2 - 3 min and centrifuged at 13000 rpm for 5 min. 800 µL supernatant was collected. Each well 
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in the plate was washed with 1 mL methanol twice. The washing solution was collected with the 
supernatant and dried in the vacuum concentrator. The residue was re-suspended in 35 µL water. 
All the samples were analyzed by the HPLC method described above. The experiments were 
repeated three times. 
3.2.8 Optimized Inhibition Assay   
According to the preliminary studies, PE concentration for inhibition study was determined 
as 50 μM, which was within the range of analytical sensitivity, as well as within the range of GI 
concentrations following an oral dose. This concentration had little to do with plasma 
concentrations, since we focused on inhibiting pre-systemic rather than systemic metabolism of 
PE. The incubation time was set from 14 hrs to 19 hrs, which was within the linear range of 
incubation time. For the inhibition study, cells were incubated with 0.5 mL DMEM containing 
1% non-essential amino acid (pH 7.4) with PE (50 μM) ± inhibitor (100 μM) for 14 hrs to 19 hrs 
at 37 
o
C with 5% CO2. Ascorbic acid (when present) was added at a concentration of 1000 μM. 
For the combination of curcumin, pterostilbene, resveratrol, and zingerone, four compounds 
were all at the concentration of 50 μM. After incubation, the extracellular buffer was collected. 
The cell lysate experiments and analysis with the HPLC method were exactly the same as 
described above. The experiments were repeated three times. 
3.2.9 Data Description and Statistical Analysis 
The data were processed with GraphPad Prism 5. Linear regression was used to determine 
the linear range of incubation time for the remaining 1-naphthol and sulfate formation in LS180 
cell model. Linear regression was also used to determine the linear range of incubation time for 
the fraction of the remaining PE. The statistically significant differences between the control 
group (PE incubated with LS180 cells in absence of phenolic dietary compounds) and the treated 
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groups (PE incubated with LS180 cells in presence of phenolic dietary compounds or 
combinations) were determined by one-way ANOVA followed by Dunnett’s post hoc test (p < 
0.05). The extent of PE disappearance in the control was considered 100%. The extent of PE 
disappearance in the treated group with phenolic dietary compounds or the combinations was 
calculated by the amount of PE disappearance in the treated group divided by the amount of PE 
disappearance in the control. The extent of PE disappearance was expressed as % of the control. 
Standard error of the mean was calculated by the formula as follows:  
n
CVCV 2treated
2
control 
 
CVcontrol was the coefficient of variation of the control group. CVtreated was the coefficient of 
variation of the treated group. n was the number of observations, which was 3 in this case.  
3.3 RESULTS 
When 1-naphthol (10 μM) was incubated with LS180 cells for 0, 0.5, 1, and 2 hrs, it was 
efficiently sulfated in LS180 cells during short incubation time (shown in Figure 3.2). It was 
linear at least up to 2 hrs incubation in linear regression analysis with r
2 
= 0.9688 for the 
remaining 1-naphthol (A) and r
2 
= 0.9958 for 1-naphthol sulfate formation (B). The mass balance 
at 0.5, 1, and 2 hrs was 90 ± 1%, 101 ± 1%, and 121 ± 2% (mean ± SD), respectively.  
The fraction of the remaining PE decreased with time over 40 hrs when incubated with 
LS180 cells at the concentration of 50 μM (shown in Figure 3.3). The linear range for incubation 
time was from 0 to 24 hrs with r
2 
= 0.9579.  
Figure 3.4 shows PE disappearance over a range of concentrations. It seems PE did not 
saturate the metabolism in LS180 cell model even at a very high concentration (3525 μM). This 
may be due to the involvement of rate-limiting transport kinetics of PE in LS180 cell system. 
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The transporters responsible for uptake of PE may become saturated before the enzymes. 
Alternatively, it may reflect multiple metabolizing enzymes playing a role, from high affinity at 
low doses to lower affinity at higher doses. During the incubation time, the enzymes appeared to 
consume PE without saturation.  
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Figure 3.2. Remaining 1-Naphthol and 1-Naphthol Sulfate Formation over 2 hrs in LS180 
Cells 
 
The total amount of 1-naphthol decreased with time when incubated with LS180 cells (in 12-well 
plates 4 days after plating) over 2 hrs at an initial concentration of 10 μM (A). The formation of 
1-naphthol sulfate increased with time over 2 hrs (B). The values are expressed as mean ± SD (n 
= 3) in these figures. The error bar is invisible. Both the remaining 1-naphthol and 1-naphthol 
sulfate formation were linear at least up to 2 hrs incubation.  
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Figure 3.3. Fraction of Remaining Phenylephrine over 40 hrs in LS180 Cells 
 
The fraction of the remaining PE decreased with time when incubated with LS180 cells (in 12-
well plates 4 days after plating) over 40 hrs at an initial concentration of 50 μM. The values are 
expressed as mean ± SD (n = 3) in this figure. The linear range for incubation time was from 0 to 
24 hrs.  
 
 
 
 
 
 
 
 
  
38 
 
 
 
0 1000 2000 3000 4000
0
100
200
300
400
500
Concentration of PE (M)
A
m
o
u
n
t 
o
f 
P
E
 D
is
a
p
p
ea
re
d
 (
n
m
o
l)
 
Figure 3.4. Phenylephrine Disappearance over a Broad Range of Concentrations in LS180 
Cells 
 
PE was incubated with LS180 cells (in 12-well plates 4 days after plating) covering a wide range 
of concentrations (1 - 3525 μM) for 18 hrs. The values are expressed as mean ± SD (n = 3) in 
this figure. PE did not saturate the metabolism in LS180 cells even at the highest concentration 
(3525 μM) in this experiment.  
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As Table 3.3 and Table 3.4 show, co-incubation for 14 - 19 hrs with some phenolic dietary 
compounds or combinations of phenolic dietary compounds significantly decreased the extent of 
PE disappearance. The extent of disappearance of PE (control = 503 ± 127 pmol/hr, mean ± SD) 
was significantly (p < 0.05) decreased by curcumin, guaiacol, isoeugenol, pterostilbene, 
resveratrol, zingerone, and the combinations of eugenol + propylparaben, propylparaben + 
vanillin, eugenol + propylparaben + vanillin + ascorbic acid, eugenol + vanillin, and 
pterostilbene + zingerone. The combinations of curcumin + resveratrol and curcumin + 
pterostilbene + resveratrol + zingerone almost completely inhibited PE disappearance.  
When eugenol, propylparaben, or vanillin was used alone, the extent of PE disappearance 
was 53.8%, 90.2%, and 133% of the control, respectively, which were not significantly different 
from the control. However, the combinations of eugenol + propylparaben, propylparaben + 
vanillin, eugenol + vanillin decreased the extent of PE disappearance to 42.6%, 37.0%, and 
57.5%, respectively. These combinations significantly decreased the extent of PE disappearance 
as compared to the control. This suggests synergy when eugenol, propylparaben, or vanillin was 
used with other compounds. 
From these experiments it is known that these phenolic dietary compounds can inhibit PE 
disappearance in LS180 cell model. The calculated logP values of the phenolic dietary 
compounds are around 2 - 3 for almost all the phenolic dietary compounds except naringin. Also 
PE was stable in the DMEM buffer during the incubation time. Therefore, the inhibition of 
disappearance of PE in LS180 cells is probably due to the inhibition of PE metabolism.  
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Table 3.3. Effects of Phenolic Dietary Compounds on Phenylephrine Disappearance  
Compound 
Extent of PE Disappearance 
(as % of control) 
SEM 
Propylparaben 53.8% 43.5% 
Vanillin 90.2% 24.4% 
Propyl gallate 114% 28% 
*Curcumin 24.5% 14.0% 
*Zingerone 52.4% 14.6% 
Methylparaben 75.9% 14.0% 
Ethylvanillin 76.5% 11.0% 
*Resveratrol 14.2% 28.0% 
Quercetin 48.7% 9.2% 
Naringin 75.7% 8.3% 
Eugenol 133% 30% 
*Guaiacol 51.3% 8.0% 
*Pterostilbene 70.6% 4.2% 
*Isoeugenol 73.9% 4.3% 
 
The asterisk indicates significant difference between the control and the treated group with 
phenolic dietary compounds. The extent of PE disappearance in the control was considered 
100%. The extent of PE disappearance in the treated group (as % of the control) was calculated 
by the amount of PE disappearance in the treated group divided by the amount of PE 
disappearance in the control. SEM was calculated by the formula discussed in the method section. 
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Table 3.4. Effects of Combinations of Phenolic Dietary Compounds on Phenylephrine 
Disappearance  
Compound  
Extent of PE 
Disappearance 
(as % of control)  
SEM 
Propylparaben + Ascorbic acid  56.4%  45.0% 
*Eugenol + Propylparaben + Vanillin + Ascorbic acid  31.1%  10.9% 
*Propylparaben + Vanillin  37.0%  11.2% 
*Eugenol + Propylparaben  42.6%  8.4% 
*Eugenol + Vanillin  57.5%  20.6% 
*Curcumin + Resveratrol  0.0%  - 
*Curcumin + Pterostilbene + Resveratrol + Zingerone  0.0%  - 
*Pterostilbene + Zingerone  36.5%  7.0% 
 
The asterisk indicates significant difference between the control and the treated group with the 
combinations of phenolic dietary compounds. The extent of PE disappearance in the control was 
considered 100%. The extent of PE disappearance in the treated group (as % of the control) was 
calculated by the amount of PE disappearance in the treated group divided by the amount of PE 
disappearance in the control. SEM was calculated by the formula discussed in the method section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
42 
 
3.4 DISCUSSION AND CONCLUSIONS 
There are many human intestinal in vitro models available to screen potential sulfation 
inhibitors, such as recombinant enzymes, cytosol, S9 fraction, and cells. Among them, intact cell 
systems are preferred over subcellular fractions, because as excipients in the formulation, 
phenolic dietary compounds, are desired to not only inhibit the sulfation of PE, but also to be 
able to cross the intestinal cell membrane, preferably by passive diffusion, to reach the enzymes 
and achieve the desired inhibition. In situ human intestinal perfusion, Ussing chamber, intestinal 
slice, primary cells have advantages as intact systems. But they are seldom used due to 
complicated technologies, limited availability, or short-time viability [125]. Cell lines are 
convenient methods to be used to investigate drug metabolism. It has been reported that 
acetaminophen sulfation does not occur in Caco-2 cells grown in a flask, probably due to the 
incomplete cell differentiation [126]. Cell differentiation is necessary for Caco-2 cells to express 
all the SULTs [127].  Caco-2 cells need long-term culture (21 - 24 days) to fully achieve cell 
differentiation, which is the limitation of this cell line.  
In this study, LS180 cells were used as a tool to investigate the sulfation inhibition of 
phenolic dietary compounds. LS180 cell is a human colon adenocarcinoma epithelial cell line. 
The sulfation activity in LS180 cells has been reported with acetaminophen as the substrate. 
When acetaminophen is incubated with intact LS180 cells, the formation of acetaminophen 
sulfate is observed [80]. SULT1A1, SULT1A3/4, SULT1E1, and SULT2A1 are responsible for 
acetaminophen sulfation [128, 129]. SULT 1A1*2 and SULT1A2*2 polymorphisms have been 
found in LS180 cell line. These polymorphisms may cause decreased enzyme activities in LS180 
cells [130]. The expression of SULT1A3 in LS180 cells is unclear in the literature. However, our 
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studies show LS180 cells had SULT1A3-like activity in that they sulfated 1-naphthol and PE, 
which are two known SULT1A3 substrates [51, 123].  
According to the characterization of drug metabolism enzymes in LS180 cells, UGT 1A1, 
UGT 1A6, and UGT2B15 are expressed at the messenger ribonucleic acid (mRNA) level in this 
cell line [125].  The protein expression level of these enzymes in LS180 cells have not been 
investigated in the literature. However, acetaminophen glucuronidation have been demonstrated 
in LS180 cells consistent with UGT activities in this cell line [80]. Sulfation is a major metabolic 
pathway for PE pre-systemic metabolism. Glucuronidation is a minor metabolic pathway for PE 
pre-systemic metabolism. In our study, the disappearance of PE was measured, which could be 
due to non-SULT metabolism (i.e., UGTs). This is one of the limitations in this study.    
MAO and aldehyde dehydrogenase (ALDH) expression or activities have not been reported 
in LS180 cells. 3-Hydroxymandelic acid, the final metabolite from monoamine oxidation 
pathway of PE metabolism (Figure 1.2), was not observed when PE was incubated with LS180 
cells. This could be due to the lack of either MAO or ALDH in this cell line.  
Another limitation for LS180 cells is that it is a human colon adenocarcinoma cell line, 
which cannot exactly represent small intestine, where most drug absorption occurs. The enzyme 
activities in cell lines are usually lower than small intestine [130]. 
Although PE metabolism in LS180 cells was tested over a broad range of concentrations, PE 
did not saturate the metabolism even at 3525 μM, which is probably due to the involvement of 
transport kinetics of PE in LS180 cell model. According to the physicochemical properties of PE, 
PE is a highly hydrophilic small molecule and ionized at the physiological pH. The uptake of PE 
into cells is probably mediated by active transporters. According to the renal clearance of PE, PE 
undergoes net tubular secretion in kidney (shown in Table 1.2). PE also has large volume of 
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distribution at steady state (shown in Table 1.2). These support the involvement of drug 
transporters for PE. However the transporters responsible for the uptake of PE are not clear in the 
literature. These transporters could be saturated before the enzymes, especially if the expression 
level of these transporters in LS180 cells is very low. There is no direct literature evidence 
showing that the uptake of PE into cells is mediated by transporters. But several compounds with 
structure similarities as PE have been found to be taken up into cells by transporters. Using 
human jejunal perfusion, the uptake of levodopa into intestine is found to be mediated by active 
transporters for large neutral amino acids [131].  The amino acid,  L-leucine, significantly 
decreased the uptake of levodopa in the intestine, which could be as the result of competing for 
the transporters with levodopa [131]. In Caco-2 cell model, phenylalanine has been proved to 
transport across both the apical side and basolateral side by transporters [132]. The uptake 
transporters found in LS180 cells at mRNA level are organic cation transporter3, organic anion 
transporter2, and novel organic cation transporter2 [125]. But none of the uptake transporters 
have been studied and reported at the protein expression level. 1-Naphthol underwent fast 
metabolism in LS180 cells as compared to PE. 1-Naphthol crosses the cell membrane by passive 
diffusion mechanism [133]. Slow PE metabolism in LS180 cells could be also due to the low 
expression of the transporters for PE uptake on LS180 cell membrane.  
An intact system, like LS180 cells, could be used as a model to screen the potential inhibitors 
for PE sulfation, but it is not suitable for studying the enzyme kinetics with PE. Subcellular 
fractions like intestinal and hepatic cytosol can be used to investigate the kinetics for PE 
sulfation and inhibition of PE sulfation with dietary inhibitors. 
When eugenol, propylparaben, or vanillin was used alone, the extent of PE disappearance 
was not significantly different from the control. However, the combinations of eugenol + 
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propylparaben, propylparaben + vanillin, eugenol + vanillin significantly decreased the extent of 
PE disappearance as compared to the control. This suggests synergism when eugenol, 
propylparaben, or vanillin was used with other compounds. The synergistic effect is probably 
due to the concentration-dependent metabolism, which is observed in both Phase I and Phase II 
metabolism. The metabolism of 4-methoxybiphenyl in rat hepatocytes has a different pattern, 
dependent on the concentration of 4-methoxybiphenyl. 4-Methoxybiphenyl is converted to 4-
hydroxybiphenyl and further metabolized to its sulfate and glucuronide. Below 25 μM, the 
percentage of each metabolite formed remains the same. Above 25 μM, the percentage of sulfate 
decreases proportionally with the concentration. 4-Hydroxybiphenyl and its glucuronide increase 
proportionally with the concentration [134].  This is because SULTs have higher affinity than 
UGTs [51]. At low concentration, such substrates are metabolized by SULTs. But at high 
concentration of substrates, SULTs are saturated and UGTs play a major role in conjugation of 
the substrates. This is very common in substrates for both SULTs and UGTs. Since PE is also a 
substrate for both SULTs and UGTs, this could occur in PE metabolism. According to the 
clinical studies for PE, four metabolites are detected in urine after oral administration of 24.6 mg 
PE over 8 hrs, which are 30% 3-hydroxymandelic acid, 6% 3-hydroxyphenylglycol sulfate, 47% 
PE sulfate, and 12% PE glucuronide [20].  In this study, much more PE sulfate is formed than PE 
glucuronide probably due to its relatively low dose level of PE. If the dose of PE is increased, the 
metabolism pattern may change, and glucuronidation may become major metabolic pathway for 
PE.  Another example found in the literature is that phenolic compounds harmol and phenol shift 
from sulfation to glucuronidation when increasing their intravenous dose in an in vivo rat study 
[135]. In rat hepatocytes, the observation is the same as an in vivo study in rat [135]. A similar 
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shift from sulfation to glucuronidation is also observed in acetaminophen when increasing the 
dose level in a rat in vivo model [136].  
In the presence of certain inhibitors, some metabolic pathways may be inhibited and other 
metabolic pathways or enzyme isoforms, which are not affected by the inhibitors, may contribute 
more to the metabolism of the substrates. For example when inhibitors for harmol sulfation are 
applied with harmol in a liver perfusion model, the sulfation of harmol decreases to 10% of the 
control, the total clearance is not changed for harmol and glucuronidation increases to play a 
major role for harmol metabolism in liver [137]. Eugenol, propylparaben, and vanillin may block 
PE metabolic pathway mediated by different enzymes or enzyme isoforms. When applying only 
eugenol, propylparaben, or vanillin, PE may go to the other metabolic pathways that are not 
blocked by the compound. But when applying the combinations, all the pathways for PE 
metabolism were blocked. Therefore, the significant decline in the disappearance of PE was 
observed with the combinations of eugenol + propylparaben, propylparaben + vanillin, eugenol + 
vanillin.  
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CHAPTER 4 
 
CHEMICAL SYNTHESIS AND CHARACTERIZATION OF R-(-)-PHENYLEPHRINE 
SULFATE AND R-(-)-ETILEFRINE SULFATE 
 
 
 
 
4.1 INTRODUCTION 
Sulfation is a very important reaction in Phase II metabolism, which often occurs in some 
phenols, but has also been seen in some alcohols, amines, and thiols [51]. Many endogenous 
substances and xenobiotics or their Phase I metabolites are substrates of SULTs in cytosols, 
which catalyze the transfer of the sulfonate group from the cofactor PAPS to hydroxyl, amino, or 
thiol groups [51]. In most of the cases, the sulfate formed in the biotransformation is less active 
but more water-soluble, which facilitates excretion [51].  
There are three enzymatic assays for sulfation and its inhibition studies: PAPS generation 
assay, preformed PAPS assay, and radiometric assay. The PAPS generation assay includes the 
two-step PAPS synthesis and the following sulfoconjugation. The first step of PAPS synthesis is 
that under the catalysis of adenosine-5’-triphosphate (ATP) sulfurylase, inorganic sulfate reacts 
with ATP to generate adenosine 5’- phosphosulfate (APS) and pyrophosphate. In the second step, 
PAPS is synthesized and the by-product adenosine diphosphate is formed by the reaction 
between APS and ATP with APS kinase as the catalyst. Magnesium ion is required in both 
reactions [59]. The enzymatic synthesis of PAPS in the body is a rapid process [59]. With PAPS 
as the donor of the sulfonate group, sulfation reaction gives the formation of sulfate by SULTs. 
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The PAPS generation assay is commonly used to identify or produce a large amount of the 
sulfate product for SULT substrates in old studies [138, 139]. Currently it is seldom used to 
conduct the enzyme kinetic studies for sulfation because it has multiple-step reactions and it 
seems difficult to optimize all the factors involved in the whole process. Wong et al. investigated 
the effects of pH, ATP/Mg
2+
 ratio, and their concentrations on the PAPS generation assay. They 
found the optimal condition for adrenaline sulfation is ATP and Mg
2+
 in the concentration range 
of 4 - 6 mM with the ratio of 1 at pH 9 [140]. It is unknown whether the same assay condition is 
suitable for other substrates. They also obtained the same Km value for adrenaline in both the 
PAPS generation assay and the preformed PAPS assay [140].  
The radiometric sulfation assay measures the formation of sulfate in an indirect way. The 
substrates for SULTs are incubated with radio-labeled cofactor [
35
S]PAPS in the enzymatic 
reaction, which is terminated by adding barium acetate/hydroxide and zinc sulphate to precipitate 
excess [
35
S]PAPS and protein [141]. The supernatant is taken to a scintillation vial after 
centrifugation. The radioactivity determined by the scintillation counting indicates the sulfate 
formation in the reaction [142-144]. Although the radiometric sulfation assay has been widely 
applied in the kinetic studies for sulfation and its inhibition, there are some disadvantages with it. 
The precipitation of excess [
35
S]PAPS could be incomplete. This assay is not as selective and 
specific as the one directly detecting the product of sulfate.  
The preformed PAPS assay with a validated analytical method is preferred over the other two 
assays in order to quantitate the sulfate products directly. It is necessary to synthesize the sulfate 
of the substrates as the reference standard for this assay. Compared to biosynthesis, chemical 
synthesis seems to be a more scalable strategy, which is usually used to obtain the sulfate.  
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There is no available information for the synthesis of PE/ET sulfate in the literature. But a 
large number of chemical synthesis methods for sulfate have been reported, which is very helpful 
for addressing the problem of PE/ET sulfate synthesis. Chemical synthesis of sulfate for some 
simple compounds is a single-step sulfating reaction. The sulfating reagent can be concentrated 
sulfuric acid, chlorosulfonic acid, sulfur trioxide pyridine complex, or sulfur trioxide 
triethylamine complex [145-148]. However, PE and ET have other functional groups compared 
to these compounds, which can be easily sulfated in undesired side reactions. Besides the 
phenolic group, PE and ET have aliphatic hydroxyl groups that can also react with the sulfating 
reagent. Since the hydroxyl groups of PE/ET compete for sulfation, a protecting group strategy is 
required to solve this problem. Protecting group strategy is a traditional method applied in 
chemical synthesis, which inserts two additional steps: introduction and removal of the 
protecting group [149]. The protecting group should be able to provide selective protection on 
the target functional group. It should also be compatible with the following reactions and finally 
can be removed without affecting other functional groups.  
According to the literature, there are two ways to protect the secondary hydroxyl group in 
PE/ET. One is oxidizing the secondary hydroxyl group to the ketone by Jones Oxidation with 
chromium trioxide in aqueous sulfuric acid and acetone [150]. The removal step is carried out by 
reducing agent such as sodium borohydride to convert the ketone to the secondary hydroxyl 
group [146]. Arakawa et al. synthesized norepinephrine and epinephrine sulfate by the similar 
method using starting materials noradrenaline and adrenaline instead of norepinephrine and 
epinephrine for the sulfating reaction. The ketone is eventually reduced to the hydroxyl group to 
get the racemic products of norepinephrine and epinephrine sulfates [146]. The design of the 
synthetic route for PE/ET sulfate with this method is shown in Figure 4.1. The first step is Jones 
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Oxidation with chromium trioxide in aqueous sulfuric acid and acetone to oxidize the secondary 
hydroxyl group in PE/ET to the ketone at room temperature. This oxidation does not affect the 
phenolic group in PE/ET. The second reaction is sulfating at the phenolic group with sulfur 
trioxide pyridine complex in the solvent of pyridine at 60 
o
C, followed by the reduction with 
sodium borohydride in ethanol at ambient temperature. The final product is the racemic mixture. 
A chiral column is required for further isolation and purification to gain R-(-)-PE/ET sulfate, 
which is the disadvantage of this method. The advantage of this synthetic route is that all the 
reactions are classic and facile. 
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Figure 4.1. Synthetic Route for Phenylephrine/Etilefrine Sulfate by Protecting the 
Secondary Hydroxyl Group with Jones Oxidation  
 
PE: R = CH3; ET: R = C2H5. RT: room temperature. This figure shows the potential route for 
PE/ET sulfate synthesis with the protecting group strategy. The asterisk indicates the chiral 
center. The final product is a racemic mixture. 
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The other protecting group method is esterification of the aliphatic hydroxyl group in PE/ET 
with the use of trifluoroacetic anhydride. The reaction may also occur at the secondary amine 
group in PE/ET to form the amide. But trifluoroacetic anhydride does not stably esterify the 
phenolic group, which ensures the success in the protecting group strategy. This has been 
demonstrated in the synthesis of 2,2,2-trifluoro-N-(3-hydroxy-4-methoxybenzyl)-N-(4-
hydroxyphenethyl)acetamide from 5-((4-hydroxyphenethylamino)methyl)-2-methoxyphenol in 
the supplementary material [151]. Although the mole ratio of trifluoroacetic anhydride to the 
reactant is around 4:1, there is no O-acylation at the phenolic group during the reaction [151]. 
The synthetic route for PE/ET sulfate with this protecting group method is shown in Figure 4.2. 
After protecting the secondary hydroxyl group, the sulfating reaction at the phenolic group is 
carried out by adding sulfur trioxide pyridine complex and stirring at 60 
o
C in pyridine. The 
protecting group is removed by hydrolysis with aqueous potassium bicarbonate at 30 
o
C. The pH 
of the potassium bicarbonate solution (100 mg/mL) is about 8.5. In this pH condition, 
trifluoroacetate ester is easily hydrolyzed [152]. The amide can also undergo hydrolysis in the 
basic pH range. This pH value does not favor the hydrolysis of sulfate. Sulfate hydrolysis is 
promoted dramatically in the acidic pH range (pH < 4) [153]. Sulfate is not very sensitive to mild 
alkalinity. The alkaline condition (pH > 10) only leads to very weak sulfate hydrolysis [153]. If 
the initial compound PE/ET is R-form, using this method can obtain the final product as R-(-)-
PE/ET sulfate without isolation of the racemic mixture by chiral column, which is the advantage 
of this method as compared to the first method described above.  
Therefore this synthetic route in Figure 4.2 was selected to synthesize R-(-)-PE/ET sulfate in 
our lab.  
 
  
53 
 
 
Figure 4.2. Synthetic Route for Phenylephrine/Etilefrine Sulfate by Protecting the 
Secondary Hydroxyl Group with Esterification  
 
PE: R = CH3; ET: R = C2H5. RT: room temperature. The figure shows the potential route for 
PE/ET sulfate synthesis with the protecting group strategy.  
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4.2 MATERIALS AND METHODS 
4.2.1 Chemicals and Reagents   
L-phenylephrine (base) was purchased from AK Scientific, Inc. (Mountain View, CA). ET 
hydrochloride was purchased from Frontier Scientific Services (Newark, NJ). Sulfur trioxide 
pyridine complex, tech. (48.8 - 50.3% active SO3) was purchased from Acros Organics (Fair 
Lawn, NJ). Trifluoroacetic anhydride was purchased from Oakwood Chemical (West Columbia, 
SC).  
Acetonitrile, dichloromethane, and methanol were purchased from Avantor Performance 
Materials, Inc. (Center Valley, PA). Ammonium acetate, dimethyl sulfoxide, potassium 
bicarbonate, sodium hydroxide, and triethylamine were purchased from Fisher Scientific (Fair 
Lawn, NJ). Ethyl acetate was purchased from Mallinckrodt Baker, Inc. (Phillipsburg, NJ). 
Hexane, hydrochloric acid, and pyridine were purchased from EMD Chemicals Inc. (Gibbstown, 
NJ). Isopropyl alcohol was purchased from Avantor Performance Materials, Inc. (Phillipsburg, 
NJ). Trifluoroacetic acid was purchased from Alfa Aesar (Ward Hill, MA). 
4.2.2. Apparatus 
pH indicator paper was purchased from EMD Chemicals Inc. (Gibbstown, NJ). Silica gel 
TLC plates were purchased from Analtech, Inc. (Newark, DE). Silica gel flash columns, strong 
cation-exchange flash columns, and semi-preparative HILIC column (250 × 10 mm, 5 μm) were 
purchased from Bonna-Agela Technologies (Wilmington, DE). Varian Microsorb-MV 100-3 
C18 column (100 × 4.6 mm, 3 μm) was purchased from Agilent Technologies (Santa Clara, CA).  
Savant refrigerated vapor trap was purchased from Thermo Scientific (Waltham, MA).  
The lyophilizer was purchased from Labconco (Kansas City, MO). 
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The semi-preparative HPLC system included Waters 600 controller, Waters 717 plus 
autosampler (Waters Corporation, Milford, MA), PerkinElmer Series 200 vacuum degasser 
(PerkinElmer, Waltham, MA), Eppendorf column heater, remote Eppendorf TC-50 (Eppendorf, 
Hamburg, Germany), Shimadzu SPD-6A UV spectrophotometric detector (Shimadzu, Kyoto, 
Japan), Waters 474 scanning FLU detector (Waters Corporation, Milford, MA), PeakSimple 
chromatography data system SRI Model 302, and PeakSimple 2000 chromatography integration 
software (SRI Instruments, Torrance, CA).  
The chromatographic experiments were conducted by the HPLC systems including Waters 
2695 separation module, Waters 2487 dual λ absorbance detector, and Waters 2475 multi λ FLU 
detector (Waters Corporation, Milford, MA). 
API4000 Q TRAP MS (Applied Biosystems Sciex, Concord, Canada) with turbo 
electrospray ion (ESI) source was utilized in negative ion mode for characterizing PE and ET 
sulfate. Analyst software Version 1.5 was used for data collection and processing. 
NMR 400 MHz spectrometer was purchased from Bruker (Billerica, MA).  
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4.2.3 Reaction I  
 
 
Figure 4.3. Reaction I for Synthesis of Trifluoro-acetic acid 1-(3-hydroxy-phenyl)-2-
[methyl-(2,2,2-trifluoro-acetyl)-amino]-ethyl ester/Trifluoro-acetic acid 2-[ethyl-(2,2,2-
trifluoro-acetyl)-amino]-1-(3-hydroxy-phenyl)-ethyl ester 
 
PE: R = CH3; ET: R = C2H5; Trifluoro-acetic acid 1-(3-hydroxy-phenyl)-2-[methyl-(2,2,2-
trifluoro-acetyl)-amino]-ethyl ester (1): R = CH3;  Trifluoro-acetic acid 2-[ethyl-(2,2,2-trifluoro-
acetyl)-amino]-1-(3-hydroxy-phenyl)-ethyl ester (2): R = C2H5. RT: room temperature.  
 
The reaction for synthesis of PE/ET trifluoroacetic acid derivatives is shown in Figure 4.3. 
Trifluoroacetic anhydride (835 μL, 5.98 mmol) was added to a suspension of PE base (100 mg, 
0.598 mmol) in anhydrous methylene chloride (2 mL). For ET hydrochloride (100 mg, 0.46 
mmol), trifluoroacetic anhydride (642 μL, 4.60 mmol) was added to conduct the reaction. The 
mole ratio of trifluoroacetic anhydride to PE/ET was 10:1. The reaction mixture was stirred at 
room temperature and monitored by silica gel TLC. PE/ET could be identified by silica gel TLC 
plate with the mobile phase composed of 15% methanol, 42.5% ethyl acetate, and 42.5% hexane. 
The formation of PE/ET trifluoroacetic acid derivatives could also be detected by silica gel TLC 
plate with the mobile phase composed of 30% ethyl acetate and 70% hexane. Two PE/ET 
trifluoroacetic acid derivatives were observed by this method. According to their molecular 
weight confirmed by MS, they were PE/ET with protecting groups on both the hydroxyl and 
amine groups (1)/(2) (Figure 4.3) and by-products shown in Figure 4.4, which could be PE/ET 
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with protection on either the hydroxyl group (3)/(4) or the amine group (5)/(6). After 24 hrs 
PE/ET was completely consumed and the reaction was quenched by slowly adding methanol (1 
mL) under stirring at room temperature. The solvent was dried under reduced pressure. The 
viscous residue was dissolved in ethyl acetate (1 mL). Most of the by-products in ethyl acetate 
were removed by extraction with 0.1 M hydrochloric acid (2 mL) into the aqueous layer three 
times. This indicated it was much more likely that the by-product was PE/ET with protection on 
the hydroxyl group (3)/(4). The organic layer with most (1)/(2) dissolved in it was evaporated 
under reduced pressure. Further purification was conducted by silica gel flash column 
chromatography with a step-wise gradient method (0 - 15% ethyl acetate in hexane) to yield 
(1)/(2) with a little amount of (3)/(4) or (5)/(6).  
 
 
Figure 4.4. Potential By-products from Reaction I 
 
Trifluoro-acetic acid 1-(3-hydroxy-phenyl)-2-methylamino-ethyl ester (3): R = CH3; Trifluoro-
acetic acid 2-ethylamino-1-(3-hydroxy-phenyl)-ethyl ester (4): R = C2H5; 2,2,2-Trifluoro-N-[2-
hydroxy-2-(3-hydroxy-phenyl)-ethyl]-N-methyl-acetamide (5): R = CH3; N-Ethyl-2,2,2-trifluoro-
N-[2-hydroxy-2-(3-hydroxy-phenyl)-ethyl]-acetamide (6): R = C2H5.  
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4.2.4 Reaction II 
 
 
Figure 4.5. Reaction II for Synthesis of Phenylephrine/Etilefrine Sulfate 
 
PE: R = CH3; ET: R = C2H5; Trifluoro-acetic acid 1-(3-hydroxy-phenyl)-2-[methyl-(2,2,2-
trifluoro-acetyl)-amino]-ethyl ester (1): R = CH3;  Trifluoro-acetic acid 2-[ethyl-(2,2,2-trifluoro-
acetyl)-amino]-1-(3-hydroxy-phenyl)-ethyl ester (2): R = C2H5; 3-(2-(2,2,2-Trifluoro-N-
methylacetamido)-1-(2,2,2-trifluoroacetoxy)ethyl)phenyl sulfate (7): R = CH3; 3-(2-(N-Ethyl-
2,2,2-trifluoroacetamido)-1-(2,2,2-trifluoroacetoxy)ethyl)phenyl sulfate (8): R = C2H5. 
 
The reaction for synthesis of PE/ET sulfate is shown in Figure 4.5. The products (1)/(2) from 
Reaction I were dissolved in anhydrous pyridine (2 mL). Sulfur trioxide pyridine complex (0.3 g) 
was added to start the reaction. Under anhydrous condition the reaction mixture was stirred at 60 
o
C with reflux for 3 hrs. The pyridine solvent was immediately dried under reduced pressure 
after the reaction. Potassium bicarbonate solution (100 mg/mL) was slowly added to the 
remaining white solid until it was completely dissolved and no bubbles appeared. The pH value 
was checked with the pH indicator paper and adjusted to 8.5 with potassium bicarbonate solution 
(100 mg/mL). The reaction was stirred at 30 
o
C for 3 hrs and then the pH was adjusted to 7.0 
with 0.1 M hydrochloric acid. The solution was dried down under reduced pressure. PE/ET 
sulfate was extracted by methanol three times and the solvent was evaporated under reduced 
pressure. The resulting solid was dissolved in water and loaded to a strong cation-exchange flash 
column (NH4
+
 form) to remove PE/ET. The further isolation and purification was accomplished 
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by a semi-preparative HILIC column (250 × 10 mm, 5 μm) with isocratic elution in a mobile 
phase composed of 3.5 g ammonium acetate, 48 mL water, 86 mL methanol, 95 mL acetonitrile, 
770 mL isopropyl alcohol. The fraction of the product PE/ET sulfate was collected and dried 
down in the vacuum. The solid was then dissolved in water and the solution was evaporated by 
lyophilization to remove the volatile salts ammonium acetate and yield the final product as 
yellow solid in the salt form.  
4.2.5 Identification and Characterization of PE/ET Sulfate 
Both the proton and carbon NMR were performed with the solvent of methanol-d to identify 
the structures of the synthesized PE/ET sulfate. The molecular weight of PE/ET sulfate was 
determined by the MS. The HPLC method was used to test the purity of PE/ET sulfate with a 
C18 column (100 × 4.6 mm, 3 μm, 40 oC) at the flow rate of 1 mL/min by the isocratic elution (5% 
acetonitrile, 95% (6.5 mM triethylamine and 13 mM trifluoroacetic acid in water)) and UV 
detection at the wavelength of 254 nm.  
4.2.6 Chemical Hydrolysis of PE/ET Sulfate 
The standard compounds of PE/ET sulfate are not available and the chemical synthesis has 
never been reported in the literature. PE/ET sulfate has both cation and anion within the same 
molecule in a broad pH range. The intramolecular ionic bond could form in PE/ET sulfate. 
PE/ET sulfate molecule could form the salt with ammonium acetate in the mobile phase as well. 
Due to the complexity of PE/ET sulfate existing forms (intramolecular salt and ammonium salt), 
the molecular weight of PE/ET sulfate was uncertain and it was difficult to determine the molar 
concentration of PE/ET sulfate. Since PE/ET reference compounds are commercially available, 
acid-based hydrolysis of PE/ET sulfate was applied to determine its molar concentration by 
comparing the disappearance of PE/ET sulfate with the formation of PE/ET. PE/ET sulfate in 
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dimethyl sulfoxide (DMSO) was diluted by 1:500 with 1 M hydrochloric acid and incubated at 
37 
o
C for 0 hr and 3 hrs. PE/ET in 1 M hydrochloric acid at the concentration of 20 μM was also 
incubated at 37 
o
C for 0 hr and 3 hrs to test their stability in the acidic solution. After incubation, 
50 μL of 2 M sodium hydroxide was added to 100 μL of 1 M hydrochloric acid with PE/ET or 
PE/ET sulfate in it. The solution was mixed well by vortex and injected into the HPLC for 
analysis.  
PE/ET and its sulfate were analyzed with a C18 column (100 × 4.6 mm, 3 μm, 40 oC) at the 
flow rate of 1 mL/min with the gradient elution. The mobile phase A was 6.5 mM triethylamine 
and 13 mM trifluoroacetic acid in water and B was acetonitrile. A was kept at 100% from 0 to 2 
min and then B was steadily increased to 50% from 2 to 6 min. PE sulfate and PE were eluted at 
2.9 and 3.5 min, respectively. ET sulfate and ET were eluted at 4.8 and 5.0 min, respectively. 
After the elution of the sulfate and the parent compound, B was reduced to 0% from 6 to 8 min 
and maintained until 10 min. PE/ET and its sulfate were detected by FLU with excitation 
wavelength at 270 nm and emission wavelength at 305 nm. The standard curve for PE/ET in the 
solution was linear from 0.03 to 30 μM with r2 > 0.99.   
During the incubation, the disappearance of PE/ET sulfate was equal to the formation of 
PE/ET in the unit of mole. The equation used to calculate the original concentration of PE/ET 
sulfate in the solution is shown as follows. Thus the concentration of PE/ET sulfate in the stock 
solution was 500 times the original concentration of PE/ET sulfate in the solution. 
 
hrs 3after peak  sulfate PE/ET ofheight   the-hr  0at peak  sulfate PE/ET ofheight  the
3hrsafter ion concentrat mole PE/ET increased the
hr 0at peak  sulfate PE/ET ofheight  the
solutionin ion concentrat mole original sulfate PE/ET

 
 
 
  
61 
 
4.3 RESULTS 
PE sulfate salt yielded 12%.  
For PE sulfate, the proton NMR spectrum is shown in Figure 4.6.  
1
H-NMR (400 MHz, MeOD): δ 2.71 (3H, s, -CH3), 3.13 (2H, m, -CH2-), 4.93 (1H, m, -CH-), 
7.23 (2H, m, -CH=), 7.35 (1H, m, -CH=), 7.38 (1H, m, -CH=). 
The carbon NMR spectrum of PE sulfate is shown in Figure 4.7.  
13
C-NMR (100 MHz, MeOD): δ 33.90, 56.71, 69.85, 120.10, 122.48, 123.28, 130.55, 143.62, 
154.36. 
MS (ESI): m/z [M-H]
-
 calculated for C9H12NO5S:246.26; found: 245.8. 
The HPLC was used to test the apparent purity of the synthesized PE sulfate (shown in 
Figure 4.8). The results from the purity test are listed in Table 4.1. The peak for PE sulfate was 
sharp and symmetric.  
 
Table 4.1. HPLC Purity Test for Phenylephrine Sulfate 
Peak Retention Time (min)  Peak Height Peak Area (μV*sec) Area (%) 
PE Sulfate 1.73 152658 624053 98.77 
Impurity I 2.35 699 4498 0.71 
Impurity II 3.79 543 3240 0.51 
 
The acid-based hydrolysis of PE sulfate was conducted to determine the molar concentration 
of PE sulfate in the stock solution by analyzing the formation of PE during the incubation with 
the reference compound.   
ET sulfate salt yielded 8%. 
For ET sulfate, the proton NMR spectrum is shown in Figure 4.9.  
1
H-NMR (400 MHz, MeOD): δ 1.31 (3H, t, J = 7.32 MHz, -CH3), 3.09 (4H, m, -CH2-), 4.93 
(1H, m, -CH-), 7.24 (2H, m, -CH=), 7.35 (1H, m, -CH=), 7.39 (1H, m, -CH=). 
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The carbon NMR spectrum of ET sulfate is shown in Figure 4.10. 
13
C-NMR (100 MHz, MeOD): δ 30.65, 44.16, 54.58, 69.96, 120.12, 122.57, 123.22, 130.58, 
143.58, 154.38.  
MS (ESI): m/z [M-H]
-
 calculated for C10H14NO5S: 260.29; found: 259.2. 
The HPLC was used to test the apparent purity of the synthesized ET sulfate (shown in 
Figure 4.11). The results from the purity test are listed in Table 4.2. The peak for ET sulfate was 
sharp and symmetric.  
 
Table 4.2. HPLC Purity Test for Etilefrine Sulfate 
Peak Retention Time (min)  Peak Height Peak Area (μV*sec) Area (%) 
ET Sulfate 2.22 250677 1179719 99.94 
Impurity  5.64 152 673 0.06 
 
The acid-based hydrolysis of ET sulfate was conducted to determine the molar concentration 
of ET sulfate in the stock solution by analyzing the formation of ET during the incubation with 
the reference compound. 
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Figure 4.6. 
1
H-NMR Spectrum for Phenylephrine Sulfate  
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Figure 4.7. 
13
C-NMR Spectrum for Phenylephrine Sulfate  
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Figure 4.8. HPLC Purity Test for Phenylephrine Sulfate 
  
66 
 
 
Figure 4.9. 
1
H-NMR Spectrum for Etilefrine Sulfate  
  
67 
 
 
Figure 4.10. 
13
C-NMR Spectrum for Etilefrine Sulfate 
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Figure 4.11. HPLC Purity Test for Etilefrine Sulfate 
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4.4 DISCUSSION AND CONCLUSIONS 
In Reaction I, since trifluoroacetic anhydride can easily react with water to produce 
trifluoroacetic acid, it was very important to maintain the anhydrous condition throughout the 
entire reaction.  
Although excess trifluoroacetic anhydride was added leading to the mole ratio of 
trifluoroacetic anhydride to PE/ET equal to 10:1, PE/ET with protection on either the hydroxyl 
group (3)/(4) or the amine group (5)/(6) was still detected after reaction. Reaction I and the 
following purification yielded PE and ET with protection on both the hydroxyl and amine groups 
(1)/(2) 76 mg and 109 mg, respectively, containing a trace amount of (3)/(4) or (5)/(6).  
When Reaction I was conducted in the ice bath under the condition that the mole ratio of 
trifluoroacetic anhydride to PE was 1:1, both PE with two protecting groups and PE with only 
one protecting group could be identified by silica gel TLC.  This demonstrates the products 
formed from the reaction were not dependent on the mole ratio of trifluoroacetic anhydride to 
PE/ET.  
      When the protecting group was introduced for ET sulfate synthesis, pyridine was first used as 
the solvent for the reaction. Because ET was in the salt form as ET hydrochloride, it was 
considered that excess pyridine can react with ET hydrochloride to form pyridine hydrochloride. 
Therefore although ET hydrochloride salts were added to the reaction, they behaved like ET base 
in the solvent of pyridine. However, this method failed several times. When trifluoroacetic 
anhydride was added to initiate the reaction, a large amount of fume can be observed. The reason 
was not clear. Instead of pyridine, methylene chloride was used as the solvent and the reaction 
was accomplished. Two compounds (ET with two protecting groups and ET with only one 
protecting group) were detected from this reaction, which was the same observation from the 
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first-step reaction for PE sulfate synthesis. The products from Reaction I were not dependent on 
the form of PE/ET.    
In Reaction II, it was necessary to use the fresh reagent sulfur trioxide pyridine complex to 
ensure the anhydrous condition. This reagent is very easy to degrade in moist air. It should be 
stored in the vacuum desiccator and should not be kept for a long time. Otherwise the poor 
quality of the reagent can definitely affect the reaction. Anhydrous pyridine was preferred as the 
solvent for the reaction.   
The intermediate was not purified after the sulfating reaction with sulfur trioxide pyridine 
complex. Potassium bicarbonate solution was added and the hydrolysis reaction was carried out 
immediately at 30 
o
C. The reason for not purifying the intermediate was that PE/ET sulfate was 
generated promptly when adding potassium bicarbonate solution, which was detected by LC-
MS/MS. In order to obtain higher yield, the purification of the intermediate after the sulfating 
reaction was eliminated.  
The last step for the synthesis was removal of the protecting group. It was first conducted by 
base-catalyzed hydrolysis with sodium bicarbonate (100 mg/mL). The reaction was very slow 
and not complete at room temperature or 30 
o
C. When changing the base to potassium 
bicarbonate (100 mg/mL), the reaction was still very slow and incomplete at room temperature. 
When the temperature was increased to 30 
o
C, the reaction can be finished in 3 hrs. Also at this 
pH and temperature, the sulfate group did not hydrolyze. When the pH was increased to 13 (0.1 
M NaOH), the hydrolysis of the sulfate group was rapid.   
The most difficult part of the synthesis was the isolation and purification of PE/ET sulfate 
after Reaction II. The silica gel flash column was tried to purify the compound with gradient 
elution. Even when the composition of the mobile phase was increased to 50% methanol in 
  
71 
 
methylene chloride, PE/ET sulfate was not eluted. This was probably because the final product 
PE/ET sulfate is a very polar and ionized compound, which may stick to the silica gel column. 
Since PE/ET sulfate has strongly anionic sulfate group, amine flash column was used as weak 
anion exchange column to isolate the compound. The amine column was conditioned with 10 
column volume of methanol and then washed with 20 column volume of 5% acetic acid. PE/ET 
sulfate was dissolved in water and loaded into the flash column system. A step-wise gradient 
elution was applied with 0 to 100% 1 M NaH2PO4 (pH 4.6) in water. PE/ET sulfate was not 
eluted even at the highest ionic strength (100% 1 M NaH2PO4). This could be due to the binding 
of positive charged secondary amine group of PE/ET sulfate to the counter-ion on the amino-
propyl bonded phase of the amine column. Even if PE/ET sulfate can be eluted, the products 
would contain a large amount of salts after the purification with amine column. It is necessary to 
desalt the products with a C18 flash column, on which PE/ET sulfate usually does not have any 
retention.  This could also cause a problem for purification. HILIC flash column with isocratic 
elution (3.5 g ammonium acetate, 48 mL water, 86 mL methanol, 95 mL acetonitrile, 770 mL 
isopropyl alcohol) was tried but could not retain PE/ET sulfate on it owing to the large pore size 
of the flash column. HILIC TLC was also tried for the isolation and purification. But it could not 
achieve good separation for PE/ET and PE/ET sulfate as a result of ionic bond. Finally, semi-
preparative HILIC column was tested and considered to be the best way to purify PE/ET sulfate. 
Since the mobile phase contained ammonium acetate, lyophilization was applied to remove the 
volatile salts.   
The peaks in the 
1
H-NMR and 
13
C-NMR spectra were consistent with the structure of PE/ET 
sulfate. The measured molecular weight by MS was very close to the calculated molecular 
weight of PE/ET sulfate. These results supported the successful synthesis of PE/ET sulfate.  
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In conclusion, PE and ET sulfate were chemically synthesized and purified in amounts 
greater (about 10 mg) than what can feasibly be synthesized by biosynthesis (< 1 mg). Their 
structures were verified by 
1
H-NMR, 
13
C-NMR, and MS.  
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CHAPTER 5 
 
LC-MS/MS METHOD DEVELOPMENT FOR SIMULTANEOUS QUANTITATION OF 
PHENYLEPHRINE AND ITS METABOLITES  
 
 
 
 
5.1 INTRODUCTION 
PE and its metabolites (PE sulfate and 3-hydroxymandelic acid) are small molecules with 
molecular weight of 167.21, 246.26, and 168.15, respectively. According to the structure of PE, 
it has two ionizable groups:  the secondary amine group and the phenolic group. The calculated 
pKa values of the secondary amine group and the phenolic group are 9.2 and 9.8, respectively [8]. 
PE is ionized with the positive charge on the secondary amine group in the recommended pH 
range of 2 to 8 for most silica-based columns. Besides the cationic secondary amine group, the 
metabolite PE sulfate has a sulfate group with the pKa value less than 1, which is highly anionic 
in most mobile phase conditions. Another major PE metabolite 3-hydroxymandelic acid has a 
carboxyl group with the estimated pKa value of 3.4, which could be neutral or negatively 
charged within the pH range of most columns. Like the parent compound PE, the phenolic group 
of 3-hydroxymandelic acid is uncharged in most liquid chromatography conditions. The 
calculated logP values for PE and 3-hydroxymandelic acid are 0.117 ± 0.269 and 0.291 ± 0.328, 
respectively [8].  
Since PE and its metabolites are charged and extremely hydrophilic compounds, liquid-liquid 
extraction for the sample preparation may not work. SPE is applied for extraction of PE from 
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human plasma/serum samples when the assays are developed to quantitatively analyze PE. The 
cartridges used in these studies are phenyl, WCX, and C18 phases [21-23, 29]. The WCX 
cartridge is not appropriate for PE sulfate and 3-hydroxymandelic acid because of the negative 
charge in these compounds. Since PE sulfate has much lower lipophilicity than PE, phenyl and 
C18 cartridges may not be suitable for it. The online sample clean-up with column switching 
technique could be a good option but has never been used for PE analysis in the literature.  This 
method needs a proper column which has retention for both PE and its metabolites.  
Due to their small molecular weight, ionized state, and low lipophilicity, PE and its 
metabolites have minimal retention on reversed-phase C18 columns. Most HPLC assays for PE 
developed with C18 or C8 columns use ion-pairing methods to achieve better retention [22, 23, 
30-33, 36, 37, 40]. Some columns specially designed for polar compounds are selected to 
facilitate the assay development for PE, such as CN, PEG, PFP, and HILIC columns [25-30]. 
Serotonin, dopamine, and their sulfates can also be analyzed by LC-MS/MS with PFP column, 
which ensures both enough retention and good separation [154, 155].   PGC column has been 
utilized for analysis of compounds with similar structures and chemical properties as PE, which 
may have the potential for the analysis of PE and its metabolites. An LC-MS/MS method is used 
to analyze the catecholamines in brain tissue by PGC column [156]. L-dopa and its metabolites 
are cleaned, separated and determined by column switching strategy with two PGC columns 
[157]. Other columns such as amide C16 column, phenyl column, and SCX column are also 
applied to quantitate compounds like PE [158-160]. Since PE is cation and the metabolites (PE 
sulfate and 3-hydroxymandelic acid) are anions in most mobile phase, PE and the metabolites 
should be detected under positive and negative mode in MS, respectively. Therefore, separation 
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is required for PE and its metabolites to ensure ionization under positive/negative mode when 
developing an LC-MS/MS method.  
For detection of PE, FLU, EC, UV, and MS detectors are commonly used [21-40]. UV 
detector usually has relatively high LLOQ values for PE [26, 27]. PE analysis in simple matrix 
like different pharmaceutical formulations is often performed with UV detection. The best 
LLOQ for PE by UV detector is 15.3 ng/mL in extraction of sachets reported by Olmo et al. [28]. 
PE has very strong FLU signal (excitation 270 nm, emission 305 nm), so analytical methods for 
PE with FLU detection could achieve good sensitivity.  The LLOQ in human serum samples by 
FLU detector is 5 ng/mL reported by Yamaguchi et al. [37]. PE is ionized in a broad pH range, 
which favors the EC detector. The EC detector can reach the LLOQ of 0.35 ng/mL in serum 
matrix reported by Vuma et al. [22]. The LC-MS/MS method for analyzing PE parent drug in 
human plasma has an LLOQ of 0.05 ng/mL, which is the best LLOQ value in the literature so far 
[24].  Comparing all the available analytical methods in the literature, LC-MS/MS can achieve 
the best LLOQ even in the complicated matrix like plasma. The low concentration of PE sulfate 
could not be detected by UV or FLU detectors. EC detection is unstable and less commonly 
available. The LC-MS/MS method for quantitatively analyzing PE and its metabolites (PE 
sulfate and 3-hydroxymandelic acid) is not available in the literature. Therefore, it is necessary to 
develop an LC-MS/MS method to analyze the parent drug PE and its metabolites in the 
enzymatic reaction to facilitate the enzyme kinetic study of PE sulfation in intestinal and hepatic 
cytosol as well as the inhibition study with phenolic dietary compounds.  
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5.2 MATERIALS AND METHODS  
5.2.1 Chemicals and Reagents 
ET hydrochloride was purchased from Frontier Scientific Services (Newark, NJ). 
Homovanillic acid was purchased from Sigma-Aldrich (St. Louis, MO). 3-Hydroxymandelic 
acid was purchased from PFALTZ & BAUER, Inc. (Waterbury, CT). PE hydrochloride was 
purchased from MP Biomedicals, LLC. (Solon, Ohio).  
Acetonitrile was purchased from Avantor Performance Materials, Inc. (Center Valley, PA). 
Formic acid was purchased from Fisher Scientific (Fair Lawn, NJ).  
5.2.2 Apparatus  
Pursuit 3 PFP column (50 × 2.0 mm, 3 μm) was purchased from Agilent Technologies (Fort 
Worth, Texas). Pinnacle CN column (50 × 2.1 mm, 5 μm) was purchased from Restek 
(Bellefonte, PA).  
The chromatographic experiments were conducted by two HPLC systems including 
Shimadzu HPLC system with controller SCL-10Avp, delivery pumps LC 10ADvp, solvent 
degasser DGU14A (Shimadzu, Kyoto, Japan) and Acquity UPLC system (Waters Corporation, 
Milford, MA). The column switching technique was achieved by a 10-port Cheminert switching 
valve and a microelectric actuator (Valco Instruments Co. Inc., Houston, TX). 
API4000 Q TRAP MS (Applied Biosystems Sciex, Concord, Canada) with turbo ESI source 
was utilized in negative ion mode for determining the concentrations of PE metabolites and 
positive ion mode for determining the concentration of PE by mode transition within the same 
run. Analyst software, Version 1.5 was used for data collection and processing.  
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5.2.3 Application of the Preliminary LC-MS/MS Method  
The preliminary LC-MS/MS method was applied to detect the formation of PE sulfate in 
inhibition study with LS180 cell model, which has been discussed in Chapter 3. Briefly, LS180 
cells were incubated with 0.5 mL DMEM containing 1% non-essential amino acid (pH 7.4) with 
PE (50 μM) /inhibitor (100 μM) for 18.5 hrs at 37 oC with 5% CO2. For the combination of 
curcumin, pterostilbene, resveratrol, and zingerone, four compounds were all at the concentration 
of 50 μM. After incubation, the extracellular buffer was collected. The cell extraction of 
metabolites was carried out with 1 mL methanol. Cells were scraped and collected in centrifuge 
tubes. The suspension was vortexed for 2 - 3 min and centrifuged at 13000 rpm for 5 min at 
room temperature. Supernatant (800 µL) was collected. Each well in the plate was washed with 1 
mL methanol twice. The washing solution was collected with the supernatant and dried in 
vacuum concentrator. The residue was re-suspended in 35 µL water. The samples from the 
extracellular buffer and cell lysate were analyzed by the preliminary LC-MS/MS method.  
5.2.4 LC-MS/MS Method Development  
The preliminary LC-MS/MS method could detect PE metabolites (PE sulfate and 3-
hydroxymandelic acid) but not the parent compound (PE). An LC-MS/MS method for 
simultaneous analysis of PE and its metabolites (PE sulfate and 3-hydroxymandelic acid) with 
internal standard was developed later by column switching technique (shown in Figure 5.1). The 
PFP column (60 
o
C) was used as a loading column to desalt the samples followed by the 
separation on a CN column (40 
o
C) with gradient elution, which allowed ionization of PE 
metabolites and PE under negative/positive ion mode. The internal standards (I.S.) were 
homovanillic acid and ET for negative and positive ion mode, respectively, with structures 
shown in Figure 5.2. The volume of the samples injected by Waters Acquity UPLC system was 
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25 μL. In the first 0.5 min, the mobile phase (0.4 mL/min, 0.1% formic acid in water) was 
delivered by the loading pump through the loading column and directly went to the waste to 
remove the salts in the samples (solid line in Figure 5.1). After 0.5 min, the analytical column 
was connected to the loading column by the 10-port cheminert switching valve and microelectric 
actuator. The eluting pump in the Shimadzu HPLC system delivered the mobile phase (0.5 
mL/min, A: 0.1% formic acid in water, B: 0.1% formic acid in acetonitrile) through the loading 
column followed by the analytical column and finally went to the API4000 Q TRAP MS for 
determination of PE metabolites and PE (dash line in Figure 5.1). The gradient curve for elution 
is shown in Figure 5.3 with the description of the method in Table 5.1. The mobile phase B was 
0% at the beginning and increased to 30% at 1 min, which was maintained until 2.2 min. The 
mobile phase B was then increased to 90% from 2.2 min to 3.5 min and maintained at 90% until 
5 min.  From 5 min to 5.1 min, the mobile phase B was decreased to 0% and maintained until 8 
min.  
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Figure 5.1. Column Switching Technique for LC-MS/MS Method  
 
PFP: pentafluorophenyl column; CN: cyano column. In the first 0.5 min, the mobile phase was 
delivered by the loading pump through the loading column and directly went to the waste (solid 
line). After 0.5 min, the eluting pump delivered the mobile phase through the loading column 
followed by the analytical column and finally went to the MS (dash line). 
 
 
 
 
 
Figure 5.2. Structures of Internal Standards for 3-Hydroxymandelic Acid and 
Phenylephrine 
 
Homovanillic acid is the internal standard for 3-hydroxymandelic acid. ET is the internal 
standard for PE.   
 
 
 
Loading Pump 
Eluting Pump 
Loading Column: PFP 
Analytical Column: CN Mass Spectrometer 
Waste 
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Figure 5.3. Gradient Curve for LC Method  
 
This curve shows the gradient elution based on the percentage of mobile phase B (0.1% formic 
acid in acetonitrile). 
 
 
Table 5.1. Gradient Elution for LC Method  
Time (min) A: 0.1% Formic Acid in Water (%) B: 0.1% Formic Acid in Acetonitrile (%) 
0.0 100 0 
1.0 70 30 
2.2 70 30 
3.5 10 90 
5.0 10 90 
5.1 100 0 
8.0 100 0 
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The API4000 Q TRAP MS was used for determination of PE metabolites and the parent 
compound. The ion source temperature was set at 450 
o
C. The ion transfer voltage was set to 
4500 V. The curtain gas, ion source gas 1, and ion source gas 2 were 20, 50, 23, respectively, in 
arbitrary unit. Tuning was carried out to determine the multiple reaction monitoring (MRM) 
transitions for PE and its metabolites as well as their internal standards, which are listed in Table 
5.2. The MS parameters were individually optimized for each analyte including declustering 
potential (DP), entrance potential (EP), collision energy (CE) and collision cell exit potential 
(CXP), which are listed in Table 5.3. After PE metabolites (PE sulfate and 3-hydroxymandelic 
acid) and internal standard (homovanillic acid) were eluted under the detection by the negative 
ion mode, the transition was made to the positive ion mode to facilitate the detection of PE and 
its internal standard. The retention time for PE metabolites and PE is listed in Table 5.2. The 
representative chromatography of PE metabolites and PE as well as their internal standards 
dissolved in mobile phase are shown in Figure 5.4 (negative ion mode) and Figure 5.5 (positive 
ion mode). 
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Table 5.2. MRM Transitions for PE Metabolites, PE and their Internal Standards 
Analyte  
Retention Time 
(min) 
MRM Transitions  
(Parent ion       Product ions )  
PE sulfate  1.39 246.0       166.0, 121.0, 93.0  
3-Hydroxymandelic acid  1.49 166.9       121.0, 93.2  
Homovanillic acid (I.S.)  1.90 181.0       137.0, 122.0  
PE  2.41 168.0       150.2, 135.0  
ET (I.S.)  2.64 182.0       135.2, 109.1  
 
MRM: multiple reaction monitoring.  
 
 
Table 5.3. Optimized Mass Spectrometer Parameters  
Analyte DP (V) EP (V) CE (V) CXP (V) 
PE sulfate -123 -10 -45 -10 
3-Hydroxymandelic acid -123 -10 -45 -10 
Homovanillic acid (I.S.) -53 -10 -22 -10 
PE 123 10 26 10 
ET (I.S.) 123 10 33 10 
 
DP: declustering potential; EP: entrance potential; CE: collision energy; CXP: collision cell exit 
potential. 
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Figure 5.4. Representative Chromatograph of Phenylephrine Sulfate, 3-Hydroxymandelic 
Acid, and Homovanillic Acid (I.S.) in Negative Ion Mode 
 
The peaks and retention time are shown in this figure for PE metabolites (PE sulfate and 3-
hydroxymandelic acid) and internal standard (homovanillic acid) under negative ion mode.  
Phenylephrine Sulfate 
3-Hydroxymandelic Acid  
Homovanillic Acid (I.S.)  
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Figure 5.5. Representative Chromatograph of Phenylephrine and Etilefrine (I.S.) in 
Positive Ion Mode 
 
The peaks and retention time are shown in this figure for PE and its internal standard (ET) under 
positive ion mode.  
 
 
 
 
 
 
 
 
 
Phenylephrine  
Etilefrine (I.S.) 
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5.3 RESULTS AND DISCUSSION 
From the preliminary LC-MS/MS data of the study in LS180 cell model, the formation of 3-
hydroxymandelic acid was not detected but sulfation of PE was readily apparent when PE was 
incubated with LS180 cells. The phenolic dietary compounds showing inhibitory effects on 
disappearance of PE probably inhibited the sulfation of PE in LS180 cells. PE sulfate formation 
was inhibited by 67.0 ± 4.2% (mean ± SEM, as % of control) with guaiacol and by 71.7 ± 2.6% 
with pterostilbene + zingerone. The combinations of curcumin + resveratrol and curcumin + 
pterostilbene + resveratrol + zingerone inhibited ≥ 99% of PE sulfate formation (shown in Table 
5.4). These results were consistent with those from analysis of the disappearance of PE in LS180 
cells (shown in Table 5.5).  
 
Table 5.4. Inhibition of Phenylephrine Sulfate Formation with Dietary Compounds in 
LS180 Cells 
Compound  
Inhibition of PE 
Sulfate Formation 
(as % of control) 
SEM 
*Guaiacol  67.0% 4.2% 
*Curcumin + Resveratrol  99.9% - 
*Pterostilbene + Zingerone  71.7% 2.6% 
*Curcumin + Pterostilbene + Resveratrol + Zingerone  99.3% - 
 
 
 
Table 5.5. Comparison of Phenylephrine Disappearance and Sulfate Formation with 
Dietary Compounds in LS180 Cells  
Compound  
Extent of PE 
Disappearance  
(as % of control)  
PE Sulfate 
Formation 
(as % of control)  
*Guaiacol  51.3%  33.0%  
*Curcumin + Resveratrol  0.0%  0.0795%  
*Pterostilbene + Zingerone  36.5%  28.3%  
*Curcumin + Pterostilbene + Resveratrol + Zingerone  0.0%  0.688%  
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The LC-MS/MS method for determination of PE has been reported in the literature as well as 
some methods for determination of compounds with structural similarity to PE and their 
metabolites [154-160]. It was the first time that an LC-MS/MS method was developed for 
simultaneously quantitating PE and its metabolites (PE sulfate and 3-hydroxymandelic acid). 
Many difficulties occurred during this method development, including sample preparation, 
column selection, and mobile phase modification, as described below.  
Sample preparation for analysis of PE and its metabolites was more complicated than for 
analysis of PE alone. Solid-phase extraction (Waters Oasis WCX cartridge) was successfully 
utilized to clean the plasma samples for analysis of PE alone. The solid phase is in a mixed mode 
with both weak cation-exchanger and reversed-phase resin. The carboxylic-acid-cation-
exchanger bound to the reversed phase selectively retains basic compounds. In addition, the 
reversed-phase interaction also helps with the retention. The procedure of the extraction was 
uncomplicated. The cartridge was conditioned with 3 mL methanol followed by 3 mL water. The 
plasma, spiked with PE, was loaded into the cartridge. The cartridge was washed with 3 mL 
water. Finally, PE was eluted by 500 μL 2% trifluoroacetic acid in methanol and water (80 : 20) 
three times. The recovery yield was 91% and 87% for 100 ng/mL and 10 ng/mL PE in plasma, 
respectively. The phenyl cartridges were also tested for PE plasma samples, which could not 
retain PE.  Obviously the WCX cartridge is not suitable for the extraction of PE sulfate and 3-
hydroxymandelic acid due to their anionic nature. For simultaneous detection of PE and its 
metabolites, in the same run, solid-phase extraction may not work. Liquid-liquid extraction is not 
a good option for ionized hydrophilic compounds.  
In this study, on-line clean up was used for sample preparation. The challenge was the 
selection of the loading column that would have retention for all the analytes. Many types of 
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columns were tested to see whether they can retain PE and its metabolites. Most reversed-phase 
columns such as C18, C8, phenyl columns had almost no retention for PE sulfate. The peak 
shape of PE on HILIC column was very broad with a peak width of about 1 min. Hypercarb 
column also gave very broad peaks. According to the literature, Hypercarb column in long-term 
use has the potential of oxidizing analytes, which is another disadvantage of this type of column 
[161]. The graphite material of the column can be oxidized by an oxidizer in mobile phase. The 
oxidized column then causes the oxidation of analytes [161]. PE as an analyte may be easily 
oxidized by the column. The normal-phase silica column was also tried and showed no retention 
for PE sulfate and 3-hydroxymandelic acid with 5% water in organic solvent, which was 
probably due to dissolution of silica in the presence of water. PFP was eventually selected as the 
loading column after many trials on other columns because of the good retention on this column.  
As the analytical column, good separation for PE and its metabolites was required to ensure 
the detection of PE under positive ion mode and PE metabolites under negative ion mode. 
Among all the columns tested in this study, the CN column had the best separation for PE and its 
metabolites, which was applied as the analytical column.  
For the HPLC method of PE, 6.5 mM triethylamine and 13 mM trifluoroacetic acid were 
used as the mobile phase modifier in aqueous phase. Trifluoroacetic acid can act as an ion- 
pairing agent at its high concentration, which can improve PE retention. Triethylamine as an 
additive can fix the tailing problem of PE on the column. The reason for the peak tailing could be 
that metals like sodium and potassium bound to silanol, exchange with ionized basic analytes at 
low pH. Excess triethylamine in the mobile phase could replace the metals instead of basic 
analytes. Therefore, triethylamine can reduce the peak tailing [162]. Triethylamine and 
trifluoroacetic acid can lead to ion suppression in MS. Therefore, they could not be used as the 
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mobile phase modifier in LC-MS/MS method. Instead, the volatile formic acid was used in the 
mobile phase for the LC-MS/MS method. As seen in Figure 5.4 and Figure 5.5, the peaks for 
PE and its metabolites were relatively sharp and symmetrical.  
A preliminary LC-MS/MS assay was developed, overcoming significant challenges of low 
retention, low resolution, and differing ionic detection modes for three compounds including PE 
(cationic), 3-hydroxymandelic acid (anionic), and PE sulfate (zwitterionic). Further studies on 
factors such as matrix effect, LLOQ, accuracy, precision, recovery, stability are necessary for the 
complete LC-MS/MS method validation.   
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CHAPTER 6 
 
THE EFFECT OF POTENTIAL INHIBITORS ON MONOAMINE OXIDASE A/B 
ACTIVITY  
 
 
 
 
6.1 INTRODUCTION 
The drug-drug interactions between many oral sympathomimetic amines and MAO inhibitors 
have been well studied in the literature. The most common adverse effect is high blood pressure. 
Other adverse effects include headache, chest pain, cardiac arrhythmias, circulation insufficiency, 
etc [15]. The mechanism of the interaction is that MAO inhibitors inhibit pre-systemic and 
systemic metabolism of some sympathomimetic amines, which are substrates for MAO, resulting 
in the elevated level of these sympathomimetic amines in circulation [15].  
Sympathomimetic amines can be divided into two types: direct and indirect acting amines. 
Indirect acting sympathomimetic amines stimulate the release of noradrenaline from the storage 
in the sympathetic nerve terminals to interact with postsynaptic adrenergic receptors. MAO 
inhibitors can increase the level of noradrenaline stored in the nerve terminals. These effects 
from sympathomimetic amines and MAO inhibitors cause the adverse interaction [15, 163]. 
Direct acting sympathomimetic amines bind directly to adrenergic receptors. Elimination of 
these direct acting sympathomimetics from interacting with adrenergic receptors occurs via 
metabolism by MAO and catechol-O-methyl transferase, and reuptake into presynaptic neurons. 
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Therefore, MAO inhibitors can affect indirectly acting sympathomimetic amines more than 
directly acting sympathomimetic amines such as PE [163]. 
Hypertensive crises were observed when phenylpropanolamine (50 mg) was orally 
administered to subject who had been treated with MAO inhibitor tranylcypromine (30 mg) for 
20 - 30 days [164]. A woman who was on phenelzine (15 mg) for three months suffered severe 
headache and had dramatic rise in blood pressure after she took oral phenylpropanolamine (32 
mg) [165]. A similar adverse effect occurred in a man on MAO inhibitor therapy when taking an 
appetite suppressant containing phenylpropanolamine [166]. An increase in blood pressure was 
observed when oral ephedrine was given to healthy subjects during the treatment with 
tranylcypromine as compared to that before the treatment [167].  
The interaction between PE and MAO inhibitors has been reported in the literature. When PE 
(45 mg) was administered orally to human subjects together with the MAO inhibitor phenelzine 
or tranylcypromine, blood pressure was quickly and dramatically elevated, compared to the 
baseline. As a result, an α-adrenergic receptor blocking drug, phentolamine, had to be given 
intravenously to reverse hypertension [167].  
Besides drug-drug interactions, certain food that contains substrates of MAO or MAO 
inhibitors may also cause the adverse effects with the interaction of oral sympathomimetic 
amines. The mechanism is similar as described above for the interaction of sympathomimetic 
amines and MAO inhibitors. The hypertensive effect has been reported with the food-drug 
interaction of pargyline and broad beans containing dopa [168]. The interaction between MAO 
inhibitors and tyramine in cheese and yeast causes severe hypertensive crises which has been 
found in many patients [169].  
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Some phenolic dietary compounds are not substrates for MAO, but they have inhibitory 
effects on MAO, such as curcumin, eugenol, piperine, quercetin, and resveratrol [170-175]. 
Curcumin inhibits both MAO-A and MAO-B in mouse brain after p.o. administration [170]. 
Piperine and paeonol are reversible inhibitors for both MAO-A and MAO-B in rat brain. The 
mode of inhibition with piperine on MAO-A and MAO-B is mixed and competitive inhibition, 
giving Ki values of 35.8 µM and 79.9 µM, respectively [172]. Paeonol has Ki values of 51.1 µM 
and 38.2 µM on MAO-A and MAO-B with non-competitive and competitive inhibition, 
respectively [172]. Emodin shows mixed mode inhibition on MAO-B with Ki value of 15.1 µM 
in rat brain [172]. Quercetin inhibits MAO-A activity in mouse brain [173, 174]. Resveratrol is a 
potent inhibitor of MAO-A in rat brain with IC50 and Ki of 2 µM and 2.5 µM, respectively [175]. 
Eugenol can competitively inhibit both human recombinant MAO-A and MAO-B with Ki of 26 
µM and 211 µM [171]. These phenolic compounds all lack amine groups and therefore MAO 
inhibition is unexpected and not immediately explained.  
The co-administration of sympathomimetic amines with MAO inhibitors may have severe or 
even fatal adverse effects. Some phenolic dietary compounds have been proven to be inhibitors 
of MAO-A, MAO-B or both of them. It is necessary to evaluate the inhibitory effects of the 
potential inhibitors for PE sulfation screened from LS180 cell model on MAO-A and MAO-B. 
However, the oxidative deamination of PE is followed by oxidation mediated by ALDH, 
resulting in formation of 3-hydroxymandelic acid as the terminal product of the two sequential 
enzymatic reactions. The intermediate after the first oxidative deamination reaction is not 
commercially available, which restricts the investigation of the inhibitory effects of phenolic 
dietary compounds on oxidative deamination of PE. Instead, the typical substrate of MAO-A and 
MAO-B, kynuramine, was used to test if these phenolic compounds can inhibit MAO-A or 
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MAO-B because the metabolite of kynuramine (3-(2-aminophenyl)-3-oxo-propionaldehyde) 
rapidly and spontaneously rearranges (by the Schiff base reaction) to the commercially available 
4-hydroxyquinoline (shown in Figure 6.1), which has strong FLU for sensitive detection [14].  
 
 
Figure 6.1. Kynuramine Converted to 4-Hydroxyquinoline via 3-(2-Aminophenyl)-3-oxo-
propionaldehyde  
 
6.2 MATERIALS AND METHODS 
6.2.1 Chemicals and Reagents 
Curcumin (mixture of curcumin, demethoxycurcumin and bisdemethoxycurcumin) was 
purchased from Acros Organics (New Jersey, USA). Guaiacol and isoeugenol were purchased 
from TCI America (Portland, OR). 4-Hydroxyquinoline and zingerone were purchased from Alfa 
Aesar (Heysham, Lancs, England). Kynuramine dihydrobromide was purchased from Sigma-
Aldrich (St. Louis, MO). Pterostilbene was purchased from ChromaDex (Irvine, CA). 
Resveratrol was purchasd from Beta Pharma, Inc. (New Haven, CT).  
Acetonitrile was purchased from Avantor Performance Materials, Inc. (Center Valley, PA). 
Dimethyl sulfoxide, perchloric acid (70%), sodium hydroxide, and triethylamine were purchased 
from Fisher Scientific (Fair Lawn, NJ). Potassium phosphate monobasic was purchased from 
Sigma (St. Louis, MO). Potassium phosphate dibasic was purchased from J.T.Baker 
(Phillipsburg, NJ). Trifluoroacetic acid was purchased from Alfa Aesar (Ward Hill, MA). 
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Human recombinant MAO-A, MAO-B and the control were purchased from BD Biosciences 
(San Jose, CA).   
6.2.2 Apparatus  
The chromatographic experiments were conducted by HPLC systems including Waters 2695 
separation module, Waters 2487 dual λ absorbance detector, and Waters 2475 multi λ FLU 
detector (Waters Corporation, Milford, MA). 
6.2.3 HPLC Method for Kynuramine and 4-Hydroxyquinoline 
6.2.3.1 Chromatographic Conditions and Detection  
The HPLC method was developed to simultaneously detect and quantify kynuramine and 4-
hydroxyquinoline to monitor the enzymatic reaction of human recombinant MAO-A/B.  A C18 
column (100 × 4.6 mm, 3 μm, 30 °C) was used to separate kynuramine and 4-hydroxyquinoline 
at a flow rate of 1 mL/min. The gradient elution was applied with 6.5 mM triethylamine and 13 
mM trifluoroacetic acid in water as mobile phase A and acetonitrile as mobile phase B (shown in 
Table 6.1). Kynuramine was detected by UV at 364 nm, and 4-hydroxyquinoline was detected 
by FLU (excitation 316 nm, emission 357 nm).  
 
Table 6.1. Gradient Elution for Kynuramine and 4-Hydroxyquinoline  
Time (min) Mobile Phase A (%) Mobile Phase B (%) 
0 90 10 
1 90 10 
5 50 50 
7 90 10 
8 90 10 
 
In the inhibition studies with phenolic dietary compounds, the HPLC method had to be 
modified to separate the phenolic compounds from kynuramine and 4-hydroxyquinoline to avoid 
interference, due to their FLU. When doing inhibition studies with guaiacol, the gradient method 
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was modified as follows: 10% B in A was maintained for 1 min and then the mobile phase B was 
increased to 50% in 4 min. After kynuramine and 4-hydroxyquinoline were eluted successfully, 
the mobile phase B was decreased to the original 10% in 2 min and maintained for 5 min. When 
doing inhibition studies with isoeugenol, pterostilbene, and zingerone, the gradient method was 
modified as follows: 10% B in A was maintained for 1 min and then the mobile phase B was 
increased to 50% in 4 min. The mobile phase B was further increased to 90% in 2 min and 
maintained for 2 min. After all the compounds were eluted successfully, the mobile phase B was 
decreased to the original 10% in 2 min and maintained for 4 min. The HPLC method 
modification did not change the retention time and the peak shape of kynuramine and 4-
hydroxyquinoline. It helped the elution of the phenolic dietary compounds after kynuramine and 
4-hydroxyquinoline to avoid interference in the following runs. The extension in run time was 
not expected to affect validation parameters.  
6.2.3.2 Stock Solution Preparation 
The reference standards of kynuramine and 4-hydroxyquinoline were dissolved in DMSO to 
obtain stock solution with a concentration of 50 mM and 200 mM, respectively. Further stock 
solutions were prepared by diluting the stock solution with DMSO. All the stock solutions were 
stored at -80 
o
C and protected from the light. 
6.2.3.3 Preparation of Standard Curves and Quality Controls   
The matrix solution was made by mixing MAO (0.01 mg/mL) in potassium phosphate buffer 
(100 mM, pH 7.4), 2 N NaOH, and 70% perchloric acid in the ratio of 8:3:1. Standard curves 
were prepared freshly by spiking the stock solutions in the prepared matrix solution with a 
concentration range of 2.00 - 1.00 × 10
3
 μM for kynuramine and 0.050 - 30 μM for 4-
hydroxyquinoline, which covered the concentrations in the samples. 
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The quality controls were prepared freshly by spiking the stock solutions in the prepared 
matrix solution with LLOQ (2.00 μM for kynuramine and 0.050 μM for 4-hydroxyquinoline), 
low quality control (10.0 μM for kynuramine and 0.25 μM for 4-hydroxyquinoline), medium 
quality control (300 μM for kynuramine and 7.5 μM for 4-hydroxyquinoline), high quality 
control (600 μM for kynuramine and 15 μM for 4-hydroxyquinoline).  
6.2.3.4 Sample Preparation 
For standards curves and quality controls, samples were vortexed and centrifuged for 5 min 
at 10,000 × g. The supernatant was taken and transferred to an autosampler vial. The volume 
injected into the HPLC was 100 μL. 
For samples after the enzymatic reaction, 2 N NaOH (75 µL) was added into the reaction 
mixture and followed by 70% perchloric acid (25 µL) to stop the reaction as well as precipitate 
the protein. Then the samples were vortexed and centrifuged for 5 min at 10,000 × g. The 
supernatant was taken and transferred to an autosampler vial. The volume injected into the 
HPLC was 100 μL.  
6.2.3.5 Method Validation  
The linearity of standard curves was determined by GraphPad Prism 5 using a simple linear 
model without y-intercept or first-order polynomial (straight line). r
2
 was obtained from the 
fitting and was required to be larger than 0.99.  
The LLOQ was determined with the criterion that the signal to noise ratio was 10:1 when 
compared to blank samples from matrix.   
For determination of intra-assay accuracy and precision, the quality control samples at LLOQ, 
low, medium, and high concentrations were assayed six times within the same run. 
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For determination of inter-assay accuracy and precision, the quality control samples at LLOQ, 
low, medium, and high concentrations were assayed six times in three separate runs. 
The recoveries were determined as follows: the quality control samples at LLOQ, low, 
medium, and high concentrations were compared with the samples spiked at the same final 
concentrations after sample preparation. Each concentration was assayed three times. 
For sample processing stability, the quality control samples at LLOQ, low, medium, and high 
concentrations were prepared and kept in the autosampler at 4 
o
C for 40 hrs and then injected 
into the HPLC for analysis. Each concentration was assayed six times. The criterion for stability 
was the detected concentrations of the quality control samples should be less than 15% change of 
the nominal spiked concentrations for low, medium, and high concentrations. For LLOQ, the 
detected concentration of the quality control sample should be less than 20% change of the 
nominal spiked concentrations.  
6.2.4 Preliminary Studies 
Time-dependent and MAO concentration-dependent studies were conducted to optimize the 
enzyme kinetic assay for kynuramine with MAO-A and MAO-B. Briefly, kynuramine (11.11 
µM) in 180 µL potassium phosphate buffer (100 mM, pH 7.4) was made from the stock solution 
in DMSO and pre-warmed for 5 min before initiation of the enzymatic reaction. The DMSO 
concentration in the final reaction buffer was less 0.5%. After pre-incubation, MAO-A/B (0.1 
mg/mL) in 20 µL potassium phosphate buffer (100 mM, pH 7.4) was added and mixed with the 
kynuramine solution to initiate the reaction. The final concentration of kynuramine and MAO-
A/B was 10 µM and 0.01 mg/mL in 200 µL reaction solution for the time-dependent study. The 
enzymatic reaction was stopped by 2 N NaOH (75 µL) followed with 70% perchloric acid (25 
µL) at incubation times of 10, 20, 30, 40, and 60 min. The samples were vortexed and 
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centrifuged for 5 min at 10000 × g. The supernatant was taken and injected to the HPLC with the 
method discussed above. For assessment of protein concentration-dependence, the same 
concentration of kynuramine (11.11 µM) was prepared in 180 µL potassium phosphate buffer 
(100 mM, pH 7.4) and pre-warmed for 5 min. Various MAO concentrations (0.03, 0.1, 0.3 
mg/mL) in 20 µL potassium phosphate buffer (100 mM, pH 7.4) were added and the total protein 
concentration was kept constant at 0.3 mg/mL by standardizing with the MAO control. The 
incubation time was 15 min, which was selected based on the results from the time-dependent 
study that are discussed below in the result section. The experiments were conducted six times. 
6.2.5 Optimized Enzyme Kinetic Assay and Km Determination 
The optimized incubation time and MAO concentration were selected in the linear range 
from the time-dependent and MAO concentration-dependent studies, as shown below. The final 
concentration of MAO in the reaction solution was 0.01 mg/mL. The incubation time was 15 min. 
In the optimized condition, the concentration-dependent study for kynuramine metabolism with 
MAO-A/B was carried out at the final concentrations of 2, 5, 10, 25, 50, 100, 250, 500 µM. The 
procedure of the assay was exactly the same as described above. The experiments were 
conducted three times in triplicate. GraphPad Prism 5 was applied to fit a Michaelis-Menten 
model to the data to obtain the Km value.  
6.2.6 Inhibition Screening and IC50 Determination  
 According to the Km value determined in the experiment described above, the final 
concentration of kynuramine was set at 10 µM for the inhibition assay, which was less than the 
Km values for MAO-A and MAO-B.  The incubation time was 15 min and MAO concentration 
was 0.01 mg/mL. For the inhibition screening with phenolic dietary compounds, the 
concentrations of the compounds were determined by comparing their solubility (25 
o
C, pH 7) 
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and maximum single dose concentration, which are listed in Table 6.2. If the concentration 
calculated from the maximum single dose in 250 mL water (recommended by FDA) is larger 
than the solubility of the compound, the solubility would be used to test the inhibitory effects on 
MAO-A/B. These concentrations mimicking the maximal GI concentrations are the possible 
maximum concentrations of these phenolic compounds to interact with MAO. Due to the low 
oral bioavailability of these compounds, the systemic concentrations of these compounds would 
be much lower than the maximal GI concentrations, resulting in less inhibitory effects on MAO. 
The concentration used to screen the inhibitors of MAO-A/B for curcumin, guaiacol, isoeugenol, 
pterostilbene, resveratrol, and zingerone was 140, 435, 110, 270, 94, and 51 µM, respectively. 
The experiments were conducted six times. The data were processed with GraphPad Prism 5. 
Significant differences between control and treated group were determined by a one-way 
ANOVA followed by Dunnett’s post hoc test (p < 0.05). If the compounds at these 
concentrations significantly decrease the formation of 4-hydroxyquinoline, further studies would 
be accomplished to determine their IC50 for the inhibition of MAO-A/B.  
The condition of the IC50 study was incubation of kynuramine (10 µM) and a broad 
concentration range of inhibitors with MAO-A/B (0.01 mg/mL) for 15 min. For MAO-A, the 
concentration range is listed as follows and shown in Figure 6.10: curcumin 0.0001 - 100 μM, 
guaiacol 0.1 - 1800 μM, isoeugenol 0.0001 - 100 μM, pterostilbene 0.001 - 250 μM, resveratrol 
0.001 - 90 μM, and zingerone 0.0001 - 400 μM. For MAO-B, the concentration range is listed as 
follows and shown in Figure 6.11: curcumin 0.001 - 100 μM, guaiacol 0.001 - 2400 μM, 
isoeugenol 0.001 - 1000 μM, pterostilbene 0.00001 - 100 μM, and resveratrol 0.01 - 90 μM. The 
procedure was exactly the same as described above. The experiments were conducted six times. 
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GraphPad Prism 5 was applied to fit the data to obtain IC50 values by using the concentration-
response equation as follows: 
t)Coefficien Hill)LogIC-((Log[I]10^+1
1
= 
500 v
vi  
This equation includes the Hill coefficient as the parameter and could help to characterize the 
inhibition.  
If the 95% confidence interval of the Hill coefficient did include 1, the concentration-
response equation with the Hill coefficient fixed at 1 was used to fit the data again by the 
following equation: 
)LogIC-(Log[I]10^+1
1
= 
500v
vi  
 
Table 6.2. Solubility and Maximum Single Dose of Phenolic Dietary Compounds 
Phenolic 
Dietary 
Compound  
Solubility 
(µM, 25 
o
C, pH 7) 
Maximum Single 
Dose (mg)  
Maximum Single 
Dose 
Concentration 
(µM) 
Relevant GI 
Concentration 
(µM)  
Curcumin 1.4E2  140 1520 140 
Guaiacol  8.6E4  54  1740 1740 
Isoeugenol  7.3E3   18  438 438 
Pterostilbene  2.7E2 250  3902 270 
Resveratrol  94   83  1455 94 
Zingerone  2.4 E4 10  206 206 
 
The calculated solubility values for phenolic dietary compounds are obtained from SciFinder [8]. 
The maximum single dose for guaiacol is from published papers [94, 95]. Maximum single doses 
for other phenolic dietary compounds are from FDA’s GRAS list, EAFUS, U.S. Federal 
Regulations, or Fenaroli’s handbook of flavor ingredients [98, 176-178]. 
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6.3 RESULTS 
6.3.1 HPLC Method Validation 
The standard curves for kynuramine were linear from 2.00 to 1.00 × 10
3
 μM with r2 > 0.99. 
The standard curves for 4-hydroxyquinoline were linear from 0.050 to 30 μM with r2 > 0.99.   
The LLOQ for kynuramine and 4-hydroxyquinoline were 2.00 μM and 0.050 μM, 
respectively.  
The intra-assay accuracy and precision for kynuramine and 4-hydroxyquinoline are listed in 
Table 6.3 and Table 6.4. The DFN and RSD for LLOQ were within 20%. The DFN and RSD 
for other quality control concentrations were within 15%. 
Table 6.3. Intra-assay Accuracy and Precision for Kynuramine 
Kynuramine Concentration (μM) N Mean DFN RSD 
2.00 6 2.01 0.6% 4.1% 
10.0 6 10.0 0.0% 0.2% 
300 6 304 1.4% 0.2% 
600 6 605 0.9% 0.1% 
 
Table 6.4. Intra-assay Accuracy and Precision for 4-Hydroxyquinoline 
4-Hydroxyquinoline Concentration (μM) N Mean  DFN RSD 
0.050 6 0.058 15.9% 5.0% 
0.25 6 0.25 1.1% 0.2% 
7.5 6 7.3 -2.1% 0.3% 
15 6 14 -3.8% 0.2% 
 
The inter-assay accuracy and precision for kynuramine and 4-hydroxyquinoline are listed in 
Table 6.5 and Table 6.6. The DFN and RSD for LLOQ were within 20%. The DFN and RSD 
for other quality control concentrations were within 15%. 
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Table 6.5. Inter-assay Accuracy and Precision for Kynuramine 
Kynuramine Concentration (μM) N Day 1 Day 2  Day 3 Mean  DFN RSD 
2.00 6 2.01 2.01 2.00 2.01 0.5% 0.2% 
10.0 6 10.0 10.0 10.0 10.0 -0.1% 0.3% 
300 6 304 304 305 305 1.5% 0.2% 
600 6 605 601 606 604 0.7% 0.5% 
 
Table 6.6. Inter-assay Accuracy and Precision for 4-Hydroxyquinoline 
4-Hydroxyquinoline Concentration (μM) N Day 1 Day 2  Day 3 Mean  DFN RSD 
0.050 6 0.058 0.058 0.060 0.059 17.2% 1.8% 
0.25 6 0.25 0.25 0.26 0.25 1.5% 1.6% 
7.5 6 7.3 7.3 7.5 7.4 -1.6% 1.5% 
15 6 14 14 15 15 -3.5% 1.9% 
 
The average recoveries for kynuramine at LLOQ, low, medium, and high concentrations 
were 98.0%, 99.1%, 100.8%, and 100.2%, respectively.  
The average recoveries for 4-hydroxyquinoline at LLOQ, low, medium, and high 
concentrations were 101.8%, 99.8%, 101.1%, and 100.2%, respectively. 
The stability tests for kynuramine and 4-hydroxyquinoline in the autosampler at 4 
o
C for 40 
hrs are listed in Table 6.7 and Table 6.8. The DFN and RSD for LLOQ were within 20%. The 
DFN and RSD for other quality control concentrations were within 15%. 
Table 6.7. Sample Processing Stability for Kynuramine 
Kynuramine Concentration (μM) N Mean  DFN RSD 
2.00 6 1.96 -1.8% 4.5% 
10.0 6 10.0 0.1% 0.2% 
300 6 305 1.7% 0.1% 
600 6 607 1.1% 0.1% 
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Table 6.8. Sample Processing Stability for 4-Hydroxyquinoline 
4-Hydroxyquinoline Concentration (μM) N Mean  DFN RSD 
0.050 6 0.059 18.3% 5.2% 
0.25 6 0.26 2.2% 0.4% 
7.5 6 7.4 -0.9% 0.4% 
15 6 15 -2.5% 0.2% 
 
6.3.2 Preliminary Studies 
The time-dependent study for oxidative deamination of kynuramine with MAO-A is shown 
in Figure 6.2. Kynuramine (10 µM) was incubated with MAO-A (0.01 mg/mL) in 200 µL 
potassium phosphate buffer (100 mM, pH 7.4) for 10, 20, 30, 40, and 60 min. The formation of 
4-hydroxyquinoline was analyzed after the enzymatic reaction. A simple linear model without y-
intercept was used to fit the data with GraphPad Prism 5. The formation of 4-hydroxyquinoline 
was linear over 60 min with the rate of 3.28 ± 0.09 nmol/mg/min (mean ± SEM) and r
2
 = 0.9887. 
According to the results from this study, the incubation time was selected as 15 min for the 
following enzymatic assay. 
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Figure 6.2. Time Dependence for Oxidative Deamination of Kynuramine with MAO-A  
 
Kynuramine (10 µM) was incubated with MAO-A (0.01 mg/mL) for 10, 20, 30, 40, and 60 min. 
A simple linear model without y-intercept was used to fit the data with GraphPad Prism 5. The 
formation of 4-hydroxyquinoline per unit protein (expressed as mean ± SD (n = 6) in this figure) 
was linear over 60 min with the rate of 3.28 ± 0.09 nmol/mg/min (mean ± SEM) and r
2
 = 0.9887. 
 
The time-dependent study for oxidative deamination of kynuramine with MAO-B is shown 
in Figure 6.3. Kynuramine (10 µM) was incubated with MAO-B (0.01 mg/mL) in 200 µL 
potassium phosphate buffer (100 mM, pH 7.4) for 10, 20, 30, 40, and 60 min. The formation of 
4-hydroxyquinoline was analyzed after the enzymatic reaction. A simple linear model without y-
intercept was used to fit the data with GraphPad Prism 5. The formation of 4-hydroxyquinoline 
was linear over 60 min with the rate of 2.70 ± 0.07 nmol/mg/min (mean ± SEM) and r
2
 = 0.9841. 
According to the results from this study, the incubation time was selected as 15 min for the 
following enzymatic assay. 
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Figure 6.3. Time Dependence for Oxidative Deamination of Kynuramine with MAO-B  
 
Kynuramine (10 µM) was incubated with MAO-B (0.01 mg/mL) for 10, 20, 30, 40, and 60 min. 
A simple linear model without y-intercept was used to fit the data with GraphPad Prism 5. The 
formation of 4-hydroxyquinoline per unit protein (expressed as mean ± SD (n = 6) in this figure) 
was linear over 60 min with the rate of 2.70 ± 0.07 nmol/mg/min (mean ± SEM) and r
2
 = 0.9841. 
The error bar is invisible. 
 
The MAO concentration-dependent study for oxidative deamination of kynuramine with 
MAO-A is shown in Figure 6.4. Kynuramine (10 µM) was incubated with MAO-A (0.003, 0.01, 
0.03 mg/mL) in 200 µL potassium phosphate buffer (100 mM, pH 7.4) for 15 min. The total 
protein concentration was kept constant at 0.03 mg/mL by compensating with the MAO control. 
The formation of 4-hydroxyquinoline was analyzed after the enzymatic reaction and showed 
linearity over 0.03 mg/mL MAO-A with the rate of 3.06 ± 0.03 nmol/mg/min (mean ± SEM) and 
r
2
 = 0.9970. According to the results from this study, the MAO-A concentration was selected as 
0.01 mg/mL for the following enzymatic assay. 
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Figure 6.4. MAO Concentration Dependence for Oxidative Deamination of Kynuramine 
with MAO-A 
 
Kynuramine (10 µM) was incubated with various concentrations of MAO-A (0.003, 0.01, 0.03 
mg/mL). A simple linear model without y-intercept was used to fit the data with GraphPad Prism 
5. The formation of 4-hydroxyquinoline per unit time (expressed as mean ± SD (n = 6) in this 
figure) was linear over 0.03 mg/mL MAO-A with the rate of 3.06 ± 0.03 nmol/mg/min (mean ± 
SEM) and r
2
 = 0.9970. 
 
The MAO concentration-dependent study for oxidative deamination of kynuramine with 
MAO-B is shown in Figure 6.5. Kynuramine (10 µM) was incubated with MAO-B (0.003, 0.01, 
0.03 mg/mL) in 200 µL potassium phosphate buffer (100 mM, pH 7.4) for 15 min. The total 
protein concentration was kept constant at 0.03 mg/mL by compensating with the MAO control. 
The formation of 4-hydroxyquinoline was analyzed after the enzymatic reaction and showed 
linearity over 0.03 mg/mL MAO-B with the rate of 3.66 ± 0.08 nmol/mg/min (mean ± SEM) and 
r
2
 = 0.9942. According to the results from this study, the MAO-B concentration was selected as 
0.01 mg/mL for the following enzymatic assay. 
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Figure 6.5. MAO Concentration Dependence for Oxidative Deamination of Kynuramine 
with MAO-B 
 
Kynuramine (10 µM) was incubated with various concentrations of MAO-B (0.003, 0.01, 0.03 
mg/mL). First-order polynomial (straight line) was used to fit the data with GraphPad Prism 5. 
The formation of 4-hydroxyquinoline per unit time (expressed as mean ± SD (n = 6) in this 
figure) was linear over 0.03 mg/mL MAO-B with the rate of 3.66 ± 0.08 nmol/mg/min (mean ± 
SEM) and r
2
 = 0.9942. 
 
6.3.3 Optimized Enzyme Kinetic Assay and Km Determination 
The concentration dependence for oxidative deamination of kynuramine with MAO-A is 
shown in Figure 6.6. Kynuramine (2, 5, 10, 25, 50, 100, 250, and 500 µM) was incubated in 200 
µL potassium phosphate buffer (100 mM, pH 7.4) for 15 min with MAO-A (0.01 mg/mL). The 
Michaelis-Menten model was used to fit the data by GraphPad Prism 5. The experiments were 
conducted 3 times in triplicate. The graph is a single representative experiment. The Km and Vmax 
were 23.1 ± 0.8 μM and 10.2 ± 0.2 nmol/min/mg (mean ± SEM), respectively. From these data, 
the concentration of kynuramine was set at 10 μM for the following inhibition study so that 
kynuramine concentration was < Km.  
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Figure 6.6. Concentration Dependence for Oxidative Deamination of Kynuramine with 
MAO-A 
 
Kynuramine (2, 5, 10, 25, 50, 100, 250, and 500 µM) was incubated with MAO-A (0.01 mg/mL). 
The Michaelis-Menten model was used to fit the data by GraphPad Prism 5. The formation of 4-
hydroxyquinoline per unit time per unit protein is expressed as mean ± SD in this figure. The 
experiments were conducted 3 times in triplicate. The graph is a single representative experiment. 
The error bar is invisible. 
 
The concentration dependence for oxidative deamination of kynuramine with MAO-B is 
shown in Figure 6.7. Kynuramine (2, 5, 10, 25, 50, 100, 250, and 500 µM) was incubated in 200 
µL potassium phosphate buffer (100 mM, pH 7.4) for 15 min with MAO-B (0.01 mg/mL). The 
Michaelis-Menten model was used to fit the data by GraphPad Prism 5. The experiments were 
conducted 3 times in triplicate. The graph is a single representative experiment. The Km and Vmax 
were 18.0 ± 2.3 μM and 7.35 ± 0.69 nmol/min/mg (mean ± SEM), respectively. From these data, 
the concentration of kynuramine was set at 10 μM for the following inhibition study so that 
kynuramine concentration was < Km.  
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Figure 6.7. Concentration Dependence for Oxidative Deamination of Kynuramine with 
MAO-B 
 
Kynuramine (2, 5, 10, 25, 50, 100, 250, and 500 µM) was incubated with MAO-B (0.01 mg/mL). 
The Michaelis-Menten model was used to fit the data by GraphPad Prism 5. The formation of 4-
hydroxyquinoline per unit time per unit protein is expressed as mean ± SD in this figure. The 
experiments were conducted 3 times in triplicate. The graph is a single representative experiment.  
 
6.3.4 Inhibition Screening and IC50 Determination 
The inhibition screening for oxidative deamination of kynuramine with MAO-A is shown in 
Figure 6.8. Kynuramine (10 µM) was incubated in 200 µL potassium phosphate buffer (100 mM, 
pH 7.4) for 15 min with MAO-A (0.01 mg/mL) and one of these phenolic dietary compounds. 
The control was the incubation with kynuramine but without any dietary compounds. The 
numbers are expressed as means ± SD and the significant differences were analyzed between the 
control (with no inhibitor) and treatments in presence of phenolic dietary compounds using one-
way ANOVA analysis followed by Dunnett’s post hoc test in GraphPad Prism 5. All the 
phenolic compounds tested in the experiments showed significant inhibition of MAO-A activity 
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with p < 0.05.  These MAO-A inhibitors were curcumin, guaiacol, isoeugenol, pterostilbene, 
resveratrol, and zingerone.  
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Figure 6.8. Inhibition of MAO-A Activity by Phenolic Dietary Compounds 
 
The inhibition screening for oxidative deamination of kynuramine with MAO-A was conducted 
with kynuramine (10 µM) incubated with MAO-A (0.01 mg/mL) and one of these phenolic 
dietary compounds. The control was the incubation with kynuramine but without any dietary 
compounds. The numbers are expressed as means ± SD (n = 6) and * indicates the significant 
differences between the control (with no inhibitor) and treatments in presence of phenolic dietary 
compounds analyzed with one-way ANOVA followed by Dunnett’s post hoc test in GraphPad 
Prism 5. Not detected indicates formation of 4-hydroxyquinoline was below LLOQ. The error 
bar is invisible. 
 
The inhibition screening for oxidative deamination of kynuramine with MAO-B is shown in 
Figure 6.9. Kynuramine (10 µM) was incubated in 200 µL potassium phosphate buffer (100 mM, 
pH 7.4) for 15 min with MAO-B (0.01 mg/mL) and one of these phenolic dietary compounds. 
The control was the incubation with kynuramine but without any dietary compounds. The 
numbers are expressed as means ± SD and the significant differences were analyzed between the 
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control (with no inhibitor) and treatments in presence of phenolic dietary compounds using one-
way ANOVA analysis followed by Dunnett’s post hoc test in GraphPad Prism 5. All the 
phenolic compounds tested in the experiments showed significant inhibition of MAO-B activity 
with p < 0.05.  These MAO-B inhibitors were curcumin, guaiacol, isoeugenol, pterostilbene, 
resveratrol, and zingerone. However, zingerone showed less than 10% inhibition at 51 µM. 
Therefore, it was not necessary to further investigate IC50 for zingerone.  
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Figure 6.9. Inhibition of MAO-B Activity by Phenolic Dietary Compounds 
 
The inhibition screening for oxidative deamination of kynuramine with MAO-B was conducted 
with kynuramine (10 µM) incubated with MAO-B (0.01 mg/mL) and one of these phenolic 
dietary compounds. The control was the incubation with kynuramine but without any dietary 
compounds. The numbers are expressed as means ± SD (n = 6) and * indicates the significant 
differences between the control (with no inhibitor) and treatments in presence of phenolic dietary 
compounds analyzed with one-way ANOVA followed by Dunnett’s post hoc test in GraphPad 
Prism 5. Not detected indicates formation of hydroxyquinoline was below LLOQ. 
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The IC50 curves for the inhibitors of kynuramine oxidative deamination with MAO-A are 
shown in Figure 6.10. MAO-A activity was measured by the formation of 4-hydroxyquinoline 
during 15 min incubation of kynuramine with MAO-A in presence of inhibitor in a broad range 
of concentrations (at least 10
4
 fold). The fractional activity is the value of MAO activity (in 
presence of inhibitor) divided by the control (in absence of inhibitor). The formation of 4-
hydroxyquinoline was under LLOD when incubating kynuramine with the negative control for 
MAO activity. IC50 values and Hill coefficient were determined from non-linear regression with 
the model described in the method section (shown in Table 6.9). The concentration-dependent 
study for inhibitors determined the IC50 values as follows: 12.9 ± 1.3 μM for curcumin, 131 ± 6 
μM for guaiacol, 3.72 ± 0.20 μM for isoeugenol, 13.4 ± 1.5 μM for pterostilbene, 0.313 ± 0.008 
μM for resveratrol, 16.3 ± 1.1 μM for zingerone.  
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Figure 6.10. Determination of IC50 for Curcumin, Guaiacol, Isoeugenol, Pterostilbene, 
Resveratrol, and Zingerone on MAO-A Activity  
 
MAO-A activity was measured by the formation of 4-hydroxyquinoline with inhibitor in a broad 
range of concentrations (at least 10
4
 fold). The Y axis is expressed as fraction of the control (in 
absence of inhibitor) and all points on the curves are expressed as mean ± SD (n = 6).  
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Table 6.9. IC50 and Hill Coefficient for MAO-A Inhibition by Phenolic Compounds 
Compound IC50 (μM) SEM Hill Coefficient SEM 
Curcumin 12.9 1.3 2.0 0.4 
Guaiacol 131 6 1.0 
 
Isoeugenol 3.72 0.20 1.2 0.1 
Pterostilbene 13.4 1.5 1.7 0.3 
Resveratrol 0.313 0.008 1.1 0.0 
Zingerone 16.3 1.1 1.0   
 
The IC50 curves for the inhibitors of kynuramine oxidative deamination with MAO-B are 
shown in Figure 6.11. MAO-B activity was measured by the formation of 4-hydroxyquinoline 
during 15 min incubation of kynuramine with MAO-B in presence of inhibitor in a broad range 
of concentrations (at least 10
4
 fold). The fractional activity is the value of MAO activity (in 
presence of inhibitor) divided by the control (in absence of inhibitor). The formation of 4-
hydroxyquinoline was under LLOD when incubating kynuramine with the negative control for 
MAO activity. IC50 values and Hill coefficient were determined from non-linear regression with 
the model described in the method section (shown in Table 6.10). The concentration-dependent 
study for inhibitors determined the IC50 values as follows: 6.30 ± 0.11 μM for curcumin, 322 ± 
27 μM for guaiacol, 102 ± 5 μM for isoeugenol, 0.138 ± 0.013 μM for pterostilbene, 15.8 ±  1.3 
μM for resveratrol. 
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Figure 6.11. Determination of IC50 for Curcumin, Guaiacol, Isoeugenol, Pterostilbene, and 
Resveratrol on MAO-B Activity  
 
MAO-B activity was measured by the formation of 4-hydroxyquinoline with inhibitor in a broad 
range of concentrations (at least 10
4
 fold). The Y axis is expressed as fraction of the control (in 
absence of inhibitor) and all points on the curves are expressed as mean ± SD (n = 6). 
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Table 6.10. IC50 and Hill Coefficient for MAO-B Inhibition by Phenolic Compounds 
Compound IC50 (μM) SEM Hill Coefficient SEM 
Curcumin 6.30 0.11 1.7 0.1 
Guaiacol 322 27 1.0 
 
Isoeugenol 102 5 2.4 0.3 
Pterostilbene 0.138 0.013 1.0 
 
Resveratrol 15.8 1.3 1.6 0.2 
 
6.4 DISCUSSION AND CONCLUSIONS 
The analytical assays for kynuramine and its MAO-mediated terminal metabolite, 4-
hydroxyquinoline, have been reported in the literature. The quantitative analysis could be simply 
achieved by fluorometric assay [179]. Other analyses are accomplished by HPLC with UV and 
FLU detection as well as LC-MS/MS method [180-183].  The phenolic compounds tested in this 
study have very strong FLU, which may interfere with the FLU signal from 4-hydroxyquinoline 
if measured in a microplate reader. Therefore, fluorometric microplate assay may not be 
selective for the detection of 4-hydroxyquinoline and thus the chromatographic separation of 4-
hydroxyquinoline and the phenolic compounds were required. Since 4-hydroxyquinoline has 
very good FLU and kynuramine can be detected by UV detection, HPLC methods with UV and 
FLU detectors were found to be quite adequate for analysis in in vitro enzyme kinetic studies. 
Herraiz et al. developed a reversed-phase HPLC method by gradient elution with 50 mM 
ammonium phosphate buffer at pH 3 and 20% of this buffer in acetonitrile [180, 181]. The 
mobile phase contained ammonium phosphate, which is easy to precipitate in the HPLC 
equipment. In order to avoid the high pressure caused by the precipitation or even damage to the 
HPLC system, modification of the mobile phase was considered and discussed in the method 
section.  
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The HPLC method for quantitative analysis of kynuramine and 4-hydroxyquinoline used 6.5 
mM triethylamine and 13 mM trifluoroacetic acid in water as its aqueous phase, which has a pH 
value around 2. The estimated most basic pKa of kynuramine is 8.4, which makes it form a 
cation under the pH condition of the mobile phase [8].  The estimated most acidic and most basic 
pKa of 4-hydroxyquinoline are 4.3 and 11.1, respectively [8]. Hence 4-hydroxyquinoline is also 
a cation at the mobile phase pH. At high concentration, trifluoroacetic acid can act as an ion-
pairing agent for cations, which can improve kynuramine and 4-hydroxyquinoline retention. 
When using the aqueous mobile phase with trifluoroacetic acid at 0.05%, there was a tailing 
problem with the peak shape. This can be caused by the ions like sodium and potassium bound to 
silanol exchanging with ionized basic analytes at low pH.  As an additive in the mobile phase, 
triethylamine can fix the tailing problem on the column. Excess triethylamine in the mobile 
phase can replace the ions instead of basic analytes. Therefore, triethylamine can reduce the peak 
tailing [162].  
An HPLC method was developed to simultaneously quantitate kynuramine and 4-
hydroxyquinoline. The formation of 4-hydroxyquinoline was measured to determine MAO 
activity. Kynuramine concentration was also measured for the mass balance calculation.  The 
mass balance ranged from 90% to 110% in all the experiments.  
For the preliminary study, the formation of 4-hydroxyquinoline was linear over 60 min with 
the protein concentration range of 0.003 mg/mL – 0.03 mg/mL, which was comparable with the 
results from the paper published by Herraiz et al. in 2006 [180]. The Km values of kynuramine 
oxidative deamination by MAO-A and MAO-B were 23 μM and 18 μM, respectively, which 
indicated MAO-A has similar affinity toward kynuramine, compared to MAO-B. In the literature, 
the Km values of kynuramine for human MAO-A and MAO-B were reported as 42 μM and 26 
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μM [182]. Another study obtained the Km values of MAO-A and MAO-B with kynuramine as 
44.1 and 90.0 μM, respectively [184]. Km values reported here were similar to the values in the 
literature, although differences in methods may account for differences in reported Km values. 
The concentration of kynuramine for the inhibition study with phenolic compounds was set at 10 
μM, which was below the Km value for both MAO-A and MAO-B.  
Theoretically, at extremely low concentration of inhibitors, the fractional enzyme activity 
should be 1, and at very high concentration of inhibitors, the fractional enzyme activity should be 
0.  Therefore, the Hill equation with two parameters instead of four parameters (including top 
and bottom as parameters) was first used to fit the IC50 data. The Hill coefficient was not fixed at 
1. This equation could also facilitate the investigation of the stoichiometry or allosterism of the 
interaction between enzyme and the inhibitor. If the 95% confidence interval of the Hill 
coefficient included 1, then the data would be plotted with one parameter equation with the Hill 
coefficient fixed at 1. This indicated the stoichiometry of binding of the enzyme and inhibitor 
was 1-to-1. According to the obtained Hill coefficient, guaiacol and zingerone was 1-to-1 
binding with MAO-A. Guaiacol and pterostilbene followed 1-to-1 binding with MAO-B. The 
Hill coefficient of resveratrol with MAO-A was 1.08, which was very close to 1, but the 95% 
confidence interval of the Hill coefficient of resveratrol with MAO-A was 1.02 to 1.16, which 
did not include 1. Curcumin, isoeugenol, pterostilbene had the Hill coefficient larger than 1, 
suggesting positive cooperativity, multiple active sites, or non-ideal inhibition behavior [185]. 
Non-ideal inhibition behavior is usually caused by protein denaturants [185]. In our experiment 
system, DMSO solvent for stock solution is such a protein denaturant. However, the 
concentration of DMSO in the final solution was less than 0.5% which was far below the 
concentration 2% as recommended by BD Biosciences, which is thought to cause minimal 
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inhibitory effects on both MAO-A and MAO-B. So the non-ideal inhibition behavior was 
unlikely to occur in our studies.  Positive cooperativity could be a possible reason. The binding 
of the inhibitor to one active site on the enzyme may increase the binding affinity of the inhibitor 
to other active sites [185]. Another possibility is that the complete inhibition of an enzyme can 
be achieved by binding of more than one molecule of inhibitor to the enzyme [185]. Further 
study is required to investigate the mechanism of inhibition which leads to the Hill coefficient 
larger than 1, including possible allosterism.   
Among these tested phenolic dietary compounds, the inhibitory effects on MAO-A and 
MAO-B in animal models were reported in the literature previously [170, 175]. However, the 
investigation was never conducted with human MAO. In this study, human recombinant MAO-A 
and MAO-B enzymes were used as models to test these phenolic compounds. Curcumin can 
inhibit MAO-A and MAO-B in mouse brain after oral administration [170]. We also found out 
that curcumin was a potent inhibitor for both MAO-A and MAO-B with IC50 as 12.9 μM and 
6.30 μM, respectively. In this study, resveratrol was the most potent inhibitor for MAO-A with 
IC50 as 0.313 μM. Resveratrol is a potent inhibitor of MAO-A in rat brain with IC50 of 2 µM and 
Ki of 2.5 µM [175]. 
Compared to the GI concentration converted from the maximum single dose, the IC50 values 
of all phenolic inhibitors on MAO-A and MAO-B are smaller than the maximum concentration 
in GI tract. The most potent inhibitor for MAO-A was resveratrol followed by isoeugenol, 
curcumin, pterostilbene, zingerone, and guaiacol in descending order of the inhibition magnitude. 
The most potent inhibitor for MAO-B was pterostilbene followed by curcumin, resveratrol, 
isoeugenol, and guaiacol in descending order of the inhibition magnitude.  
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Phenolic compounds are substrates for neither MAO-A or MAO-B. The mechanism of the 
inhibition of phenolic compounds on MAO is not clear, but none of them has been reported to 
have irreversible inhibition on MAO-A or MAO-B [171, 172]. The researchers found that they 
are reversible inhibitors with various mode of inhibition such as competitive inhibition, non-
competitive, or mixed-type inhibition [171, 172].  
The mRNA levels of MAO-A and MAO-B are similar in the liver with the ratio of the target 
mRNA to peptidylprolyl isomerase A mRNA as 0.346 and 0.476, respectively [186]. The ratio of 
MAO-A mRNA in small intestine is 0.719.  The ratio of MAO-B mRNA in small intestine is 
0.163.  The mRNA expression of MAO-A in small intestine is much higher than MAO-B [186].  
According to the literature, these phenolic MAO-A inhibitors all have low bioavailability. 
Curcumin has poor bioavailability after oral administration in humans even after a high dose of 
12 g/day, which leads to low plasma concentration [187]. At the dose 4 g, 6 g, and 8 g, the 
maximum concentration of curcumin in plasma is 0.51 μM, 0.64 μM, and 1.77 μM, respectively 
[91]. After gavage administration, the absolute bioavailability of isoeugenol in female and male 
rats is 19% and 10%, respectively. The low bioavailability of isoeugenol was also observed in 
mice as 28% for male mice and 31% for female mice after gavage bolus [188]. The peak 
concentration of resveratrol in human is very low after oral dose [119, 121].  At 25 mg, 50 mg, 
100 mg, and 150 mg dose level, the maximum concentration of resveratrol is 1.48 ng/mL, 6.59 
ng/mL, 21.4 ng/mL, and 24.8 ng/mL, respectively [121]. At higher dose level of 0.5 g, 1.0 g, 2.5 
g, and 5.0 g, the corresponding peak concentration of resveratrol is 72.6 ng/mL, 117.0 ng/mL, 
268.0 ng/mL, and 538.8 ng/mL [119]. The oral bioavailability in rats was determined as 12.5% 
after 10 mg/kg gavage administration by Lin et al. [104]. After giving rats 56 or 
168 mg/kg/day pterostilbene by gavage for 14 continuous days, the oral bioavailability is 0.8 
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[105]. The reason why these phenolic compounds have such low bioavailability is that they all 
undergo extensive pre-systemic metabolism and are converted to their metabolites before going 
to the systemic circulation [87-89, 96, 105, 106, 117-120].  
As described above, in the dose range of 25 mg to 5.0 g, the maximum concentration of 
resveratrol is in the range 1.48 to 538.8 ng/mL. Considering the plasma protein binding of 91% 
for resveratrol, the unbound peak concentration is in the range 5.84 × 10
-4
 to 0.212 μM [189]. 
With the IC50 values of 0.313 and 15.8 μM for MAO-A and MAO-B and assuming competitive 
inhibition of resveratrol on human MAO-A and MAO-B, the Ki would be 0.218 and 10.2 μM for 
MAO-A and MAO-B, respectively. Therefore, the drug-drug interaction index for MAO-A and 
MAO-B with resveratrol is calculated by unbound Cmax/Ki [190]. The drug-drug interaction index 
for MAO-A is in the range of 2.7 × 10
-3
 to 0.97. The drug-drug interaction index for MAO-B is 
in the range of 5.7 × 10
-5
 to 0.021. At high dose level of resveratrol (5.0 g), the drug-drug 
interaction on MAO-A may occur.  
Since these phenolic compounds all have relatively low bioavailability, the inhibition 
occurring after first-pass metabolism is likely to be limited. Most inhibitory effects on MAO-A 
and MAO-B would be limited to GI tract and liver. This could limit the possible side effects 
when giving PE and these phenolic MAO inhibitors together.  
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CHAPTER 7 
 
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS  
 
 
 
 
PE is the most popular nonprescription oral nasal decongestant currently on the market. It has 
been used for decades and is considered safe [7]. It has pharmacological activity as a selective 
α1-adrenergic receptor agonist [7]. But the oral bioavailability of PE is low and highly variable, 
due to its extensive first-pass metabolism [19]. The efficacy study conducted for PE shows that 
an oral dose of 10 mg PE is not significantly different from the placebo based on the effects on 
nasal airway resistance [3]. The low bioavailability and associated variability of PE probably 
cause the poor efficacy. Unlike oral bioavailability problems caused by poor solubility that may 
be solved by modified formulations, low oral bioavailability of PE is due to extensive pre-
systemic metabolism. Therefore, if the pre-systemic metabolism can be inhibited, the 
bioavailability of PE would be expected to increase with reduced variability. According to the 
clinical studies, the predominant metabolic pathways of PE after oral administration are sulfation 
and oxidative deamination [20]. Since MAO inhibitors, especially irreversible inhibitors, are 
found to increase the risk of hypertension when co-administered with sympathomimetic amines, 
they should not be systemically administered with PE [167]. In order to increase the oral 
bioavailability and eventually improve the efficacy of PE, this research project aimed to 
investigate the feasibility of inhibiting the pre-systemic sulfation of PE with some phenolic 
compounds from FDA’s “GRAS” list, EAFUS, or dietary supplements, which are generally 
considered as safe.   
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 LS180 cell line, which was demonstrated to have sulfation activity by 1-naphthol sulfation, 
was used as a model to test the inhibitory effects of these phenolic compounds on the sulfation of 
PE (50 μM). The phenolic compounds were at the concentration of 100 μM. Ascorbic acid (when 
present) was added at a concentration of 1000 μM. For the combination of curcumin, 
pterostilbene, resveratrol, and zingerone, four compounds were all at the concentration of 50 μM. 
The extent of disappearance of PE was significantly decreased with the following phenolic 
dietary compounds: curcumin, guaiacol, isoeugenol, pterostilbene, resveratrol, zingerone, and the 
combinations eugenol + propylparaben, vanillin + propylparaben, eugenol + propylparaben + 
vanillin + ascorbic acid, eugenol + vanillin, and pterostilbene + zingerone. The combinations of 
curcumin + resveratrol and curcumin + pterostilbene + resveratrol + zingerone almost 
completely inhibited PE disappearance.  
PE was stable during the incubation time in absence of LS180 cells, suggesting that these 
inhibitor treatments probably inhibited PE metabolism rather than decreasing the degradation of 
PE. Based on the LC-MS/MS observation, 3-hydroxymandelic acid, the metabolite from 
oxidative deamination of PE, was not found when PE was incubated with LS180 cells, indicating 
either MAO or ALDH is absent in this cell line. Therefore, most likely PE disappearance was 
mainly due to Phase II metabolism, particularly sulfation.  
      In order to confirm the inhibition of sulfation activity in LS180 cells by these phenolic 
dietary compounds, PE sulfate was chemically synthesized by using hydroxyl and amine-
protecting group strategy and reacting with sulfur trioxide pyridine complex. The structure of PE 
sulfate was confirmed by 
1
H- and 
13
C-NMR and MS. LC-MS/MS method with column switching 
technique was developed to quantitate PE sulfate and the parent drug PE, simultaneously. A PFP 
column was used as the loading column to desalt the samples followed by the separation on a CN 
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column with gradient elution, which allows ionization of PE metabolites and PE with negative/ 
positive mode switching.   
The formation of PE sulfate in the inhibition study using PE (50 μM) as a substrate in LS180 
cells with phenolic dietary compounds or the combinations such as guaiacol, pterostilbene + 
zingerone, curcumin + resveratrol, curcumin + pterostilbene + resveratrol + zingerone was 
analyzed by the LC-MS/MS method. The phenolic compounds were at the concentration of 100 
μM. For the combination of curcumin, pterostilbene, resveratrol, and zingerone, four compounds 
were all at the concentration of 50 μM. PE sulfate formation was inhibited by 67.0 ± 4.2% (mean 
± SEM, as % of control) with guaiacol and by 71.7 ± 2.6% with pterostilbene + zingerone. The 
combinations of curcumin + resveratrol and curcumin + pterostilbene + resveratrol + zingerone 
inhibited ≥ 99% of PE sulfate formation. These results were consistent with those from analysis 
of the disappearance of PE in LS180 cells, providing stronger evidence that the inhibitor 
treatment which showed inhibitory effects on disappearance of PE did so by inhibiting the 
sulfation of PE in LS180 cells. 
When eugenol, propylparaben, or vanillin were used alone, the extent of PE disappearance 
was not significantly different from the control. However, the combinations of eugenol + 
propylparaben, eugenol + vanillin, propylparaben + vanillin significantly decreased the extent of 
PE disappearance as compared to the control. This suggested synergism when eugenol, 
propylparaben, or vanillin was used with other compounds. 
The synergistic effect was possibly due to the concentration-dependent metabolism, which 
has been well demonstrated in the literature [20, 134-137, 191].  The metabolic pattern could be 
changed dependent on the dose of the parent drug. The contribution of certain enzymes to the 
metabolism of the drug may change with substrate concentration. Eugenol, propylparaben, and 
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vanillin may inhibit PE metabolic pathway mediated by different enzymes or enzyme isoforms. 
When applying only eugenol, propylparaben, or vanillin, PE may switch to the other metabolic 
pathways that are not inhibited by the compound. But when applying the inhibitor combinations, 
all these pathways for PE metabolism may have been blocked. Therefore, the significant decline 
in the disappearance of PE was observed with combinations of eugenol + propylparaben, eugenol 
+ vanillin, propylparaben + vanillin.  
In conclusion, several compounds and especially their combinations have shown the 
inhibitory effects on PE sulfation in LS180 cell model and could be potential compounds for co-
administration with PE to improve its oral bioavailability.  
Considering the potential safety issue related to MAO inhibition, the drug-drug interaction of 
sympathomimetic amines and MAO inhibitors may cause hypertension in patients. Thus, it was 
necessary to test the inhibitory effects of these phenolic compounds on MAO-A/B. Since the 
immediate metabolite from PE oxidative deamination by MAO is not commercially available, 
kynuramine was used as a model substrate of MAO-A/B for the inhibition study. The 
preliminary linearity studies were conducted to optimize the assay condition. The Km values for 
human recombinant MAO-A and B were 23.1 ± 0.8 μM and 18.0 ± 2.3 μM (mean ± SEM), 
respectively. The inhibition screening for oxidative deamination with MAO-A/B was using 
kynuramine as substrate at 10 µM. Significant inhibition was found with curcumin, guaiacol, 
isoeugenol, pterostilbene, resveratrol, and zingerone on both MAO-A and B at expected relevant 
GI concentrations. 
Further kinetic studies were conducted to determine the IC50 values of these inhibitors for 
MAO-A and MAO-B. The most potent inhibitor for MAO-A was resveratrol (0.313 ± 0.008 μM, 
mean ± SEM) followed by isoeugenol (3.72 ± 0.20 μM), curcumin (12.9 ± 1.3 μM), pterostilbene 
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(13.4 ± 1.5 μM), zingerone (16.3 ± 1.1 μM), and guaiacol (131 ± 6 μM). The most potent 
inhibitor for MAO-B was pterostilbene (0.138 ± 0.013 μM, mean ± SEM) followed by curcumin 
(6.30 ± 0.11 μM), resveratrol (15.8 ± 1.3 μM), isoeugenol (102 ± 5 μM), and guaiacol (322 ± 27 
μM). The phenolic compounds are substrates for neither MAO-A or MAO-B. The mechanism of 
the inhibition of phenolic compounds on MAO is not clear, but none of them have been reported 
to be irreversible inhibitors on MAO-A or MAO-B. The researchers found that they are 
reversible inhibitors with various mode of inhibition such as competitive, non-competitive, or 
mixed-type inhibition [171, 172].  
Based on the evidence from the literature, these phenolic MAO inhibitors all have low oral 
bioavailability [104, 105, 119, 121, 187, 188]. Even at very high doses, expected and observed 
plasma concentrations of these compounds are very low and sometimes could not be detected 
[119, 121, 187].  The reason why these phenolic compounds have such low bioavailability is that 
they all undergo extensive pre-systemic metabolism and are mostly converted to their 
metabolites before reaching the systemic circulation [87-89, 96, 105, 106, 117-120]. Since these 
phenolic compounds all have relatively low bioavailability, the inhibition that would occur 
systemically after first-pass metabolism is limited. Most inhibitory effects on MAO-A and 
MAO-B if any would be on the GI tract and liver. This could limit the possible side effects when 
giving PE and these phenolic MAO inhibitors together. 
So far it is not clear which phenolic dietary compound or combination could be used as 
excipients with PE to inhibit pre-systemic sulfation of PE without adverse effects (such as 
systemic MAO inhibition) and to effectively increase the oral bioavailability of PE. Future 
studies are needed for further investigation. Kinetic studies on sulfation inhibition with phenolic 
compounds using intestinal and hepatic cytosol are necessary to investigate the IC50 values of 
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these compounds. The use of recombinant SULT isoforms would also be valuable. The mode of 
inhibition is better to determine for inhibitors on sulfation as well as oxidative deamination.  
Ultimately, we anticipate designing a double-blind, randomized, cross-over study in humans 
and clinically testing a combination approach, which would enable use of each inhibitor at safe 
and clinically feasible dose, and utilize the potential synergy observed in these studies.  The 
envisioned product would therefore include PE and more than one phenolic dietary inhibitor at 
established safe doses.  The combination of inhibitors would be chosen based upon achievable 
doses, efficacy to inhibit SULT, lack of MAO inhibition at anticipated peak plasma 
concentrations, and low oral bioavailability and toxicity of the inhibitor itself.  The potential 
clinical utility of the approach would be evaluated by determining the relative bioavailability of 
PE.  
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